Quinolone derived compounds for cancer treatment

Abstract

The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R1, R2, R3, X1, X2, X3, X4, Q1, A1, A2, A3, A4, A5 and A6 are as defined in the specification, and antibody-drug conjugates (ADCs) comprising the compounds. The present invention also relates to processes for the preparation of the compounds and ADCs, pharmaceutical compositions containing them and their use in therapy, particularly for use in treating cancers.

Description

[0001]- 1 - Novel Compounds Field of the Invention The present invention relates to fused tetracyclic heteroaromatic compounds and 5 antibody-drug conjugates (ADCs) comprising the compounds. The present invention also relates to processes for the preparation of the compounds and ADCs, and to pharmaceutical compositions containing them and their use in therapy, particularly for use in treating cancers. 10 Background of the Invention Small molecules that interact with genomic DNA have a long history of use in cancer chemotherapy (e.g. cisplatin family and anthracyclines).1Such molecules target DNA indiscriminately and display broad toxicity in patients owing to their lack of molecular and biological specificity. Despite adverse toxicity, these drugs are still widely 15 deployed in the clinic.2G-quadruplexes (G4s) are four-stranded, non-canonical nucleic acid secondary structures which can form in guanine-rich DNA and RNA sequences. In the human genome, there are over 700,000 G4 forming sequences.3–5These G4 motifs are 20 particularly enriched at repetitive elements of the genome, e.g. telomeres, and at gene regulatory regions of protein-coding genes including many oncogenes. Folded DNA and RNA G4s have been visualized in human cells and tissues,6–8mapped in human chromatin and the human transcripome,9–12and overall been found to be 25 more abundant in cancer-like cells and tissues7,9. G4s have been implicated in several key genome functions such as transcription, replication, translation, telomere maintenance and epigenetic regulation.13Many G4s are likely transient and readily resolved by helicases14. Unresolved DNA G4s can 30 impede DNA polymerases causing DNA damage and requiring homologous recombination (HR) repair15,16. Some compounds, named G4 ligands (G4L), have been shown to interact with and stabilise G4s in vitro and in human chromatin17–19. Given the involvement of G4s in 35 various pivotal cellular functions and the connection to cancer biology, G4Ls have been explored as therapeutic agents and shown antiproliferative and chemosensitizing effects against cancer cell lines and tumour models18,20–22. In cancer cells, DNA G4 stabilization may interfere with replication and transcription, affect epigenetic - 2 - modifications, promote DNA damage, affect the biogenesis and interactions of coding and non-coding RNA or impair telomerase and thereby inhibit tumour growth.18,23Different G4L chemotypes have been described to mediate genome-wide perturbations, target a subset of G4 topologies and particular G4s in certain 5 oncogenes.18Cancer cells often display higher sensitivity to G4L treatment than non-cancerous cells in accordance with the higher occurrence of folded G4s in the chromatin of cancer cell lines and tissues9,22. In addition, some G4Ls are synthetic lethal with loss of various10 cellular functions24, in particular DNA damage repair25–28, suggesting a biomarker- driven therapeutic approach as well as combination treatment with other agents. Some G4Ls have shown activity in HR-deficient cells and tumour models that were resistant to PARP inhibitor treatment as well as gemcitabine-resistant pancreatic cancer cells, indicating that some G4Ls may be used to target difficult to treat certain 15 tumours with acquired resistances.25,29,30The G4L CX-5461 entered clinical trials for solid tumours with HR-deficiency mutations (NCT02719977)26. An observed reversion of BRCA2 and PALB2 confirmed the mechanism of action. The molecule was overall well tolerated, but displayed dose- 20 limiting phototoxicity.26Similarly, photosensitivity had been observed in a previous clinical trial of CX-5461 in patients with hematologic malignancies.31There is a need to provide compounds with improved pharmacological and / or physiological and / or physicochemical properties and / or those that provide a useful 25 alternative to CX-5461. Summary of the Invention A first aspect of the invention provides a compound of Formula (I): 30 Formula (I) wherein: - 3 - R1is a bicyclic or a tricyclic group, wherein the bicyclic or the tricyclic group is non-aromatic, and wherein the bicyclic or the tricyclic group may optionally be substituted with one or more groups each independently selected from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C12 saturated or 5 unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- 10 moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; R2and R3are each independently selected from hydrogen or a C1-C12 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained 15 or branched, or be or include one or more cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more halo, oxo (=O) and / or -NO2 groups, wherein the saturated hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may 20 optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; or R2and R3together with the nitrogen atom to which they are attached form a 3- to 12-membered saturated cyclic group, wherein the saturated cyclic group may optionally be substituted with one or more substituents each independently selected 25 from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more halo, oxo (=O) and / or -NO2 groups, wherein the saturated hydrocarbyl group may optionally 30 include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; X1is N, C-H, C-Hal or C-RX1; 35 X2is N, C-H, C-Hal or C-RX2; X3is N, C-H, C-Hal or C-RX3; and X4is N or C; provided that no more than three of X1, X2, X3and X4are N; - 4 - RX1, RX2and RX3are each independently selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted 5 with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form moiety; 10 Q1is O, S, N, N-H, N-RQ1, RQ1is selected from a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may 15 optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of RQ1that is directly attached to the nitrogen atom of N-RQ1is 20 a carbon atom; RQ2is selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 25 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; 30 A1is N, C-H, C-Hal or C-RA1; A2is N, C-H, C-Hal or C-RA2; A3is N, C-H, C-Hal or C-RA3; A4is N, C-H, C-Hal or C-RA4; and A5is N or C; 35 provided that no more than three of A1, A2, A3, A4and A5are N; RA1, RA2, RA3and RA4are each independently selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include - 5 - a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group 5 may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; A6is N or C; and each Hal is independently selected from a fluoro, chloro, bromo or iodo group. 10 As will be understood, and as indicated by the circles, each of the four rings in the fused tetracyclic ring system of Formula (I) is aromatic. In other words, X1, X2, X3, X4, A1, A2, A3, A4, A5, A6and Q1are selected such that each ring of the fused tetracyclic ring system of Formula (I) is aromatic. 15 In the context of the present specification, a “hydrocarbyl” substituent group or a hydrocarbyl moiety in a substituent group only includes carbon and hydrogen atoms but, unless stated otherwise, does not include any heteroatoms, such as N, O or S, in its carbon skeleton. A hydrocarbyl group / moiety may be saturated or unsaturated (including aromatic), and may be straight-chained or branched, or be or include cyclic 20 groups wherein, unless stated otherwise, the cyclic group does not include any heteroatoms, such as N, O or S, in its carbon skeleton. Examples of hydrocarbyl groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and aryl groups / moieties and combinations of all of these groups / moieties. Typically a hydrocarbyl group is a C1-C20 hydrocarbyl group. More typically a hydrocarbyl group is a C1-C15 hydrocarbyl 25 group. More typically a hydrocarbyl group is a C1-C10 hydrocarbyl group. A “hydrocarbylene” group is similarly defined as a divalent hydrocarbyl group. An “alkyl” substituent group or an alkyl moiety in a substituent group may be linear (i.e. straight-chained) or branched. Examples of alkyl groups / moieties include methyl, 30 ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl and n-pentyl groups / moieties. Unless stated otherwise, the term “alkyl” does not include “cycloalkyl”. Typically an alkyl group is a C1-C12 alkyl group. More typically an alkyl group is a C1-C6 alkyl group. An “alkylene” group is similarly defined as a divalent alkyl group. 35 An “alkenyl” substituent group or an alkenyl moiety in a substituent group refers to an unsaturated alkyl group or moiety having one or more carbon-carbon double bonds. Examples of alkenyl groups / moieties include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl and 1,4- - 6 - hexadienyl groups / moieties. Unless stated otherwise, the term “alkenyl” does not include “cycloalkenyl”. Typically an alkenyl group is a C2-C12 alkenyl group. More typically an alkenyl group is a C2-C6 alkenyl group. An “alkenylene” group is similarly defined as a divalent alkenyl group. 5 An “alkynyl” substituent group or an alkynyl moiety in a substituent group refers to an unsaturated alkyl group or moiety having one or more carbon-carbon triple bonds. Examples of alkynyl groups / moieties include ethynyl, propargyl, but-1-ynyl and but-2- ynyl groups / moieties. Typically an alkynyl group is a C2-C12 alkynyl group. More 10 typically an alkynyl group is a C2-C6 alkynyl group. An “alkynylene” group is similarly defined as a divalent alkynyl group. A “cyclic” substituent group or a cyclic moiety in a substituent group refers to any hydrocarbyl ring, wherein the hydrocarbyl ring may be saturated or unsaturated 15 (including aromatic) and may include one or more heteroatoms, e.g. N, O or S, in its carbon skeleton. Examples of cyclic groups include cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl groups as discussed below. A cyclic group may be monocyclic, bicyclic (e.g. bridged, fused or spiro), or polycyclic. Typically, a cyclic group is a 3- to 12-membered cyclic group, which means it contains from 3 to 12 ring 20 atoms. More typically, a cyclic group is a 3- to 7-membered monocyclic group, which means it contains from 3 to 7 ring atoms. A “heterocyclic” substituent group or a heterocyclic moiety in a substituent group refers to a cyclic group or moiety including one or more carbon atoms and one or 25 more (such as one, two, three or four) heteroatoms, e.g. N, O or S, in the ring structure. Examples of heterocyclic groups include heteroaryl groups as discussed below and non-aromatic heterocyclic groups such as azetinyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, dioxolanyl, oxathiolanyl, piperidinyl, tetrahydropyranyl, thianyl, 30 piperazinyl, dioxanyl, morpholinyl and thiomorpholinyl groups. A “cycloalkyl” substituent group or a cycloalkyl moiety in a substituent group refers to a saturated hydrocarbyl ring containing, for example, from 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Unless 35 stated otherwise, a cycloalkyl substituent group or moiety may include monocyclic, bicyclic or polycyclic hydrocarbyl rings. - 7 - A “cycloalkenyl” substituent group or a cycloalkenyl moiety in a substituent group refers to a non-aromatic unsaturated hydrocarbyl ring having one or more carbon- carbon double bonds and containing, for example, from 3 to 7 carbon atoms, examples of which include cyclopent-1-en-1-yl, cyclohex-1-en-1-yl and cyclohex-1,3- 5 dien-1-yl. Unless stated otherwise, a cycloalkenyl substituent group or moiety may include monocyclic, bicyclic or polycyclic hydrocarbyl rings. An “aryl” substituent group or an aryl moiety in a substituent group refers to an aromatic hydrocarbyl ring. The term “aryl” refers to monocyclic aromatic hydrocarbons 10 and polycyclic fused ring aromatic hydrocarbons wherein all of the fused ring systems (excluding any ring systems which are part of or formed by optional substituents) are aromatic. Examples of aryl groups / moieties include phenyl, naphthyl, anthracenyl and phenanthrenyl. Unless stated otherwise, the term “aryl” does not include “heteroaryl”. 15 A “heteroaryl” substituent group or a heteroaryl moiety in a substituent group refers to an aromatic heterocyclic group or moiety. The term “heteroaryl” refers to monocyclic aromatic heterocycles and polycyclic fused ring aromatic heterocycles wherein all of the fused ring systems (excluding any ring systems which are part of or formed by optional substituents) are aromatic. Examples of heteroaryl 20 groups / moieties include the following: wherein G = O, S or NH. Particular examples of 5- or 6-membered heteroaryl groups 25 include furanyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, furazanyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl groups. Unless stated otherwise, where a cyclic group or moiety is stated to be aromatic, such 30 as an aryl or a heteroaryl group, it is to be understood that each ring system within the group or moiety (excluding any ring systems which are part of or formed by optional substituents) is aromatic. Similarly, where a cyclic group or moiety is stated to be non-aromatic, such as a cycloalkyl, cycloalkenyl or non-aromatic heterocyclic group, it is to be understood that each ring system within the group or moiety - 8 - (excluding any ring systems which are part of or formed by optional substituents) is non-aromatic. And following the same convention, where a cyclic group or moiety is stated to be saturated, it is to be understood that each ring system within the group or moiety (excluding any ring systems which are part of or formed by optional 5 substituents) is saturated. For the purposes of the present specification, where a combination of moieties is referred to as one group, for example, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl, the last mentioned moiety contains the atom by which the 10 group is attached to the rest of the molecule. An example of an arylalkyl group is benzyl. As will be appreciated, in an optionally substituted moiety: - each hydrogen atom may optionally be replaced by any specified monovalent 15 substituent; - any two hydrogen atoms attached to the same carbon or nitrogen atom may optionally be replaced by any specified π-bonded substituent; - any sulphur atom may optionally be substituted with one or two of any specified π-bonded substituents; and 20 - any two hydrogen atoms attached to the same or different atoms, within the same optionally substituted group or moiety, may optionally be replaced by any specified divalent bridging substituent. Typically a substituted group comprises 1, 2, 3 or 4 substituents, more typically 1, 2 25 or 3 substituents, more typically 1 or 2 substituents, and more typically 1 substituent. Unless stated otherwise, any divalent bridging substituent (e.g. -O-, -S-, -NH-, -CH2-, -CH2-CH2-, etc.) of an optionally substituted group or moiety (e.g. R1) must only be attached to the specified group or moiety and may not be attached to a second group 30 or moiety (e.g. R2), even if the second group or moiety can itself be optionally substituted. The term “halo” includes fluoro, chloro, bromo and iodo. 35 Unless stated otherwise, where a group is prefixed by the term “halo”, such as a haloalkyl or halomethyl group, it is to be understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo and iodo. Typically, the maximum number of halo substituents is limited only - 9 - by the number of hydrogen atoms available for substitution on the corresponding group without the halo prefix. For example, a halomethyl group may contain one, two or three halo substituents. A haloethyl or halophenyl group may contain one, two, three, four or five halo substituents. Similarly, unless stated otherwise, where a group 5 is prefixed by a specific halo group, it is to be understood that the group in question is substituted with one or more of the specific halo groups. For example, the term “fluoromethyl” refers to a methyl group substituted with one, two or three fluoro groups. 10 Similarly, unless stated otherwise, where a group is said to be “halo-substituted”, it is to be understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution on the group said to be halo-substituted. For example, 15 a halo-substituted methyl group may contain one, two or three halo substituents. A halo-substituted ethyl or halo-substituted phenyl group may contain one, two, three, four or five halo substituents. Unless stated otherwise, any reference to an element is to be considered a reference 20 to all isotopes of that element. Thus, for example, unless stated otherwise any reference to hydrogen is considered to encompass all isotopes of hydrogen including deuterium and tritium. Unless stated otherwise, any reference to a compound or group is to be considered a 25 reference to all tautomers of that compound or group. Where reference is made to a hydrocarbyl or other group including one or more heteroatoms N, O or S in its carbon skeleton, or where reference is made to a carbon atom of a hydrocarbyl or other group being replaced by an N, O or S atom, what is 30 intended is that: replaced by ; CH . N .. . is replaced by; –CH2– is replaced by –NH–, –O– or –S–; –CH3 is replaced by –NH2, –OH or –SH; 35 –CH= is replaced by –N=; - 10 - CH2= is replaced by NH=, O= or S=; or CH≡ is replaced by N≡; provided that the resultant group comprises at least one carbon atom. For example, methoxy, dimethylamino and aminoethyl groups are considered to be hydrocarbyl 5 groups including one or more heteroatoms N, O or S in their carbon skeleton. Typically, the compounds of the invention contain no more than one quaternary ammonium group. More typically, the compounds of the invention contain no quaternary ammonium groups. 10 In the context of the present specification, unless otherwise stated, a Cx-Cy group is defined as a group containing from x to y carbon atoms. For example, a C1-C4 alkyl group is defined as an alkyl group containing from 1 to 4 carbon atoms. For the purposes of allocating x and y in a Cx-Cy group, optional substituents are not taken 15 into account when calculating the total number of carbon atoms in the parent group substituted with the optional substituents. For the avoidance of doubt, replacement heteroatoms, e.g. N, O or S, are not to be counted as carbon atoms when calculating the number of carbon atoms in a Cx-Cy group. For example, a morpholinyl group is to be considered a C4 heterocyclic group, not a C6 heterocyclic group. 20 For the purposes of the present specification, where it is stated that a first atom or group is “directly attached” to a second atom or group it is to be understood that the first atom or group is covalently bonded to the second atom or group with no intervening atom(s) or group(s) being present. So, for example, for the group 25 -(C=O)N(CH3)2, the carbon atom of each methyl group is directly attached to the nitrogen atom and the carbon atom of the carbonyl group is directly attached to the nitrogen atom, but the carbon atom of the carbonyl group is not directly attached to the carbon atom of either methyl group. 30 As stated in accordance with the first aspect of the invention, R1is a bicyclic or a tricyclic group, wherein the bicyclic or the tricyclic group is non-aromatic, and wherein the bicyclic or the tricyclic group may optionally be substituted with one or more groups each independently selected from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C12 saturated or unsaturated hydrocarbyl group, 35 wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O - 11 - and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. 5 The bicyclic or tricyclic group of R1may be a fused, spiro or bridged bicyclic or tricyclic group, or in the case of a tricyclic group any combination thereof. Typically, the bicyclic or tricyclic group of R1is a fused or spiro bicyclic or a fused or spiro tricyclic group, or a fused and spiro tricyclic group. More typically, the bicyclic or tricyclic group of R1is a fused bicyclic or a fused tricyclic group. 10 Typically, the bicyclic or tricyclic group of R1is a bicyclic group. For example, the bicyclic or tricyclic group of R1may be a fused, spiro or bridged bicyclic group. Typically, the bicyclic or tricyclic group of R1is a fused or spiro bicyclic group. 15 Where the bicyclic or tricyclic group of R1is a bicyclic group, typically the bicyclic group is a 6- to 13-membered bicyclic group. More typically, the bicyclic group is a 7- to 12-membered bicyclic group. Typically, the bicyclic or tricyclic group of R1is a heterocyclic group. 20 Typically, the bicyclic or tricyclic group of R1is saturated. Typically, the ring atom of the bicyclic or tricyclic group of R1that is directly attached to the remainder of the molecule is a nitrogen atom. 25 Typically, the bicyclic or tricyclic group of R1contains at least one ring nitrogen or ring oxygen atom that is not directly attached to the remainder of the molecule. More typically, the bicyclic or tricyclic group of R1contains at least one ring nitrogen atom that is not directly attached to the remainder of the molecule. 30 Where the bicyclic or tricyclic group of R1is substituted, typically it is substituted with one or more groups each independently selected from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C8 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or 35 include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl - 12 - group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. More typically, where the bicyclic or tricyclic group of R1is substituted, it is substituted with one or more fluoro groups and / or one or two oxo (=O) groups, 5 and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated 10 hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More typically, where the bicyclic or tricyclic group of R1is substituted, it is substituted with one or more fluoro groups and / or a single oxo (=O) group, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, 15 wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. More typically still, where 20 the bicyclic or tricyclic group of R1is substituted, it is substituted with one or more fluoro groups and / or a single oxo (=O) group, and / or a single group R11, wherein R11is a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro 25 groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. In one embodiment, R1is a non-aromatic fused bicyclic heterocyclic group, wherein 30 the non-aromatic fused bicyclic heterocyclic group may optionally be substituted with one or more groups each independently selected from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C8 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be 35 substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently - 13 - selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. As will be understood, in such an embodiment the fused bicyclic heterocyclic group comprises a first ring system that is directly attached to the remainder of the molecule and a second ring system that is fused to the first ring system, wherein both 5 the first and the second ring system are non-aromatic. Typically, at least one of the first and the second ring systems is saturated. More typically, both the first and the second ring systems are saturated. Typically, the first ring system contains a ring nitrogen atom that is directly attached to the remainder of the molecule. Typically, the second ring system contains a ring nitrogen atom. Typically, the fused bicyclic 10 heterocyclic group contains no more than three ring heteroatoms. More typically, the fused bicyclic heterocyclic group contains no more than two ring heteroatoms. Typically the first ring system is a 4- to 7-membered ring and the second ring system is a 4- to 7-membered ring. More typically, the first ring system is a 5- or 6- membered ring and the second ring system is a 5- or 6-membered ring. Where the 15 non-aromatic fused bicyclic heterocyclic group is substituted, typically it is substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the 20 saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More typically, where the non-aromatic fused bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups 25 and / or a single oxo (=O) group, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) 30 group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. For example, each R11may be independently selected from a -OH, -NH2, -R110, -CO-R111, -OR110, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or 35 fluorocyclopropylmethyl group, or any two R110attached to the same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms, and wherein each R111is independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or - 14 - fluorocyclopropyl group. More typically, each R11is independently selected from a -OH, -NH2, -R110, -OR110, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group, or any two R110attached to the same nitrogen atom may together form a C2-C4 5 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms. In another embodiment, R1is a saturated fused bicyclic heterocyclic group, wherein the saturated fused bicyclic heterocyclic group comprises at least one ring nitrogen 10 atom, wherein the saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, 15 wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. As will be understood, in such an embodiment the fused bicyclic heterocyclic group comprises a first ring system that is 20 directly attached to the remainder of the molecule and a second ring system that is fused to the first ring system, wherein both the first and the second ring system are saturated. Typically, the first ring system contains a ring nitrogen atom that is directly attached to the remainder of the molecule. Typically, the second ring system contains a ring nitrogen atom. Typically, the fused bicyclic heterocyclic group contains no more 25 than three ring heteroatoms. More typically, the fused bicyclic heterocyclic group contains no more than two ring heteroatoms. Typically the first ring system is a 4- to 7-membered ring and the second ring system is a 4- to 7-membered ring. More typically, the first ring system is a 5- or 6-membered ring and the second ring system is a 5- or 6-membered ring. Where the saturated fused bicyclic heterocyclic group is 30 substituted, typically it is substituted with one or more fluoro groups and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro 35 groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. For example, each R11may be independently selected from a -OH, -NH2, -R110, -CO-R111, -OR110, -NHR110or -N(R110)2 group, wherein each R110is independently - 15 - selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms, 5 and wherein each R111is independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically, each R11is independently selected from a -OH, -NH2, -R110, -OR110, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group, or any two R110attached to the same nitrogen atom may 10 together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms. Typically, where the saturated fused bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or one or two groups R11, wherein each R11is independently selected from a -NH2, -R110, -CO-R111, -NHR110or -N(R110)2 group, wherein each R110is 15 independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms, and wherein each R111is independently selected from a C1-C3 alkyl, C1- 20 C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. For example, each R11may be independently selected from a -NH2, -R110, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a methyl or fluoromethyl group. More typically, where the saturated fused bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or a single group selected from -R110or -CO-R111, 25 wherein if present -R110or -CO-R111is directly attached to a ring nitrogen atom of the saturated fused bicyclic heterocyclic group, wherein R110is selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, and wherein R111is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Typically, where -R110or -CO-R111is 30 directly attached to a ring nitrogen atom of the saturated fused bicyclic heterocyclic group, the ring nitrogen atom is a ring nitrogen atom of the second ring system. In a further embodiment, R1has the formula: - 16 - wherein: m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; 5 p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: m + n = 2 or 3; p + q = 2 or 3; 10 when m = 0, q is 1, 2 or 3; when n = 0, p is 1, 2 or 3; when p = 0, n is 1, 2 or 3; and when q = 0, m is 1, 2 or 3; and wherein: 15 r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group, wherein R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 20 fluorocyclopropyl group; and each R13is independently selected from a methyl or fluoromethyl group. As will be understood, in such an embodiment the compound is a compound of Formula (Ia): 25 Formula (Ia) - 17 - wherein X1-X4, A1-A6, Q1, R2, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). Typically in such an embodiment, m is 1 or 2 and n is 1 or 2. More typically, m is 1 5 and n is 1. Typically in such an embodiment, p is 0, 1 or 2 and q is 1 or 2. More typically, p is 1 or 2 and q is 1 or 2. 10 Typically in such an embodiment, r is 0 and s is 0. Thus, for example, R1may have the formula: wherein: 15 p is 0, 1 or 2; q is 1 or 2; p + q = 2 or 3; and R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group, 20 wherein R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Typically in such an example, p is 1 or 2. More typically, p is 1 and q is 1. 25 In an alternate example, R1may have the formula: wherein: p is 0, 1 or 2; q is 1 or 2; 30 p + q = 2 or 3; and R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group, - 18 - wherein R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Typically in such an example, p + q = 2. More typically, p is 0 and q is 2. 5 Typically in the above embodiments, R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. More typically, R12is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically still, R12is hydrogen or a methyl or 10 fluoromethyl group. For example, R1may have a formula selected from: 15 In a further embodiment, R1has the formula: wherein: 20 r is 0, 1 or 2; s is 0, 1 or 2; t is 1 or 2; and each R13is independently selected from a methyl or fluoromethyl group. 25 As will be understood, in such an embodiment the compound is a compound of Formula (Ib): - 19 - Formula (Ib) wherein X1-X4, A1-A6, Q1, R2, R3, R13, r, s and t are as defined in accordance with Formula (I). 5 Typically in such an embodiment, r is 0 and s is 0. Typically in such an embodiment, t is 1. 10 For example, R1may have the formula: . In yet another embodiment, R1has the formula: 15 wherein: m is 0, 1, 2 or 3; and n is 0, 1, 2 or 3; provided that m + n = 2 or 3; and wherein: 20 v is 1 or 2; r is 0, 1 or 2; s is 0, 1 or 2; and each R13is independently selected from a methyl or fluoromethyl group. - 20 - As will be understood, in such an embodiment the compound is a compound of Formula (Ic): Formula (Ic) 5 wherein X1-X4, A1-A6, Q1, R2, R3, R13, m, n, r, s and v are as defined in accordance with Formula (I). Typically in such an embodiment, m is 1 or 2 and n is 1 or 2. More typically, m is 1 and n is 1. 10 Typically in such an embodiment, v is 1. Typically in such an embodiment, r is 0 and s is 0. 15 For example, R1may have the formula: . As will be understood, where a first 4- to 7-membered ring is fused to a second 4- to 7-membered ring across two sp3hybridised ring carbon atoms, e.g. across two ring 20 carbon atoms in a saturated fused bicyclic ring system, the second ring may be fused cis- or trans- to the first ring. For example, R1may have the formula: . In an alternate embodiment, R1is a saturated fused bicyclic heterocyclic group, 25 wherein the fused bicyclic heterocyclic group comprises a first ring system that is directly attached to the remainder of the molecule and a second ring system that is fused to the first ring system, wherein both the first and the second ring system are - 21 - saturated, wherein the first ring system contains a ring carbon atom that is directly attached to the remainder of the molecule, wherein the saturated fused bicyclic heterocyclic group comprises at least one ring nitrogen atom, and wherein the saturated fused bicyclic heterocyclic group may optionally be substituted with one or 5 more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single 10 oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. Typically, the second ring system contains a ring nitrogen atom. Typically, the fused bicyclic heterocyclic group contains no more than three ring heteroatoms. More typically, the fused bicyclic heterocyclic group contains no more than two ring 15 heteroatoms. Typically the first ring system is a 4- to 7-membered ring and the second ring system is a 4- to 7-membered ring. More typically, the first ring system is a 5- or 6-membered ring and the second ring system is a 5- or 6-membered ring. Where the saturated fused bicyclic heterocyclic group is substituted, typically it is substituted with one or more fluoro groups and / or one or two groups R11, wherein 20 each R11is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single 25 heteroatom selected from N and O in its carbon skeleton. For example, each R11may be independently selected from a -OH, -NH2, -R110, -CO-R111, -OR110, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the same nitrogen atom 30 may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms, and wherein each R111is independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Typically, where the saturated fused bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or one or 35 two groups R11, wherein each R11is independently selected from a -NH2, -R110, -CO-R111, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the - 22 - same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms, and wherein each R111is independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically, where the saturated fused 5 bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or a single group selected from -R110or -CO-R111, wherein if present -R110or -CO-R111is directly attached to a ring nitrogen atom of the saturated fused bicyclic heterocyclic group, wherein R110is selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, 10 and wherein R111is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Typically, where -R110or -CO-R111is directly attached to a ring nitrogen atom of the saturated fused bicyclic heterocyclic group, the ring nitrogen atom is a ring nitrogen atom of the second ring system. 15 In one embodiment, R1has the formula: wherein: 20 m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: 25 m + n = 2 or 3; and p + q = 2 or 3; and wherein: r is 0, 1 or 2; s is 0, 1 or 2; 30 R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group, wherein R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and - 23 - each R13is independently selected from a methyl or fluoromethyl group. As will be understood, in such an embodiment the compound is a compound of Formula (Id): 5 Formula (Id) wherein X1-X4, A1-A6, Q1, R2, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 10 Typically in such an embodiment: when m = 0, q is 1, 2 or 3; when n = 0, p is 1, 2 or 3; when p = 0, n is 1, 2 or 3; and when q = 0, m is 1, 2 or 3; 15 Typically in such an embodiment, m is 1 or 2 and n is 1 or 2. More typically, m is 1 and n is 1. Typically in such an embodiment, p is 0, 1 or 2 and q is 1 or 2. More typically, p is 1 20 or 2 and q is 1 or 2. More typically still, p is 1 and q is 1. Typically in such an embodiment, r is 0 and s is 0. Typically in such an embodiment, R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1- 25 C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. More typically, R12is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. For example, R1may have the formula: - 24 - . In another embodiment, R1is a non-aromatic spiro bicyclic heterocyclic group, wherein the non-aromatic spiro bicyclic heterocyclic group may optionally be 5 substituted with one or more groups each independently selected from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C8 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, 10 wherein the hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. As will be understood, in such an embodiment the 15 spiro bicyclic heterocyclic group comprises a first ring system that is directly attached to the remainder of the molecule and a second ring system that shares a spiro ring atom with the first ring system, wherein both the first and the second ring system are non-aromatic. Typically, at least one of the first and the second ring systems is saturated. More typically, both the first and the second ring systems are saturated. 20 Typically, the first ring system contains a ring nitrogen atom that is directly attached to the remainder of the molecule. Typically, the second ring system contains a ring nitrogen or a ring oxygen atom. More typically, the second ring system contains a ring nitrogen atom. Typically, the spiro bicyclic heterocyclic group contains no more than three ring heteroatoms. More typically, the spiro bicyclic heterocyclic group contains25 no more than two ring heteroatoms. Typically the first ring system is a 4- to 7- membered ring and the second ring system is a 3- to 7-membered ring. More typically, the first ring system is a 5- or 6-membered ring and the second ring system is a 5- or 6-membered ring. Where the non-aromatic spiro bicyclic heterocyclic group is substituted, typically it is substituted with one or more fluoro groups and / or one or 30 two oxo (=O) groups, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) 35 group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More - 25 - typically, where the non-aromatic spiro bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or a single oxo (=O) group, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be 5 straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. For example, each R11may be independently selected from a -OH, -NH2, 10 -R110, -CO-R111, -OR110, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms, 15 and wherein each R111is independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. In another embodiment, R1is a saturated spiro bicyclic heterocyclic group, wherein the saturated spiro bicyclic heterocyclic group comprises at least one ring nitrogen 20 atom, wherein the saturated spiro bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, 25 wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. As will be understood, in such an embodiment the spiro bicyclic heterocyclic group comprises a first ring system that is 30 directly attached to the remainder of the molecule and a second ring system that shares a spiro ring atom with the first ring system, wherein both the first and the second ring system are saturated. Typically, the first ring system contains a ring nitrogen atom that is directly attached to the remainder of the molecule. Typically, the second ring system contains a ring nitrogen or a ring oxygen atom. More typically, the 35 second ring system contains a ring nitrogen atom. Typically, the spiro bicyclic heterocyclic group contains no more than three ring heteroatoms. More typically, the spiro bicyclic heterocyclic group contains no more than two ring heteroatoms. Typically the first ring system is a 4- to 7-membered ring and the second ring system is a 3- to - 26 - 7-membered ring. More typically, the first ring system is a 5- or 6-membered ring and the second ring system is a 5- or 6-membered ring. Where the saturated spiro bicyclic heterocyclic group is substituted, typically it is substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one or two groups R11, wherein each 5 R11is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single 10 heteroatom selected from N and O in its carbon skeleton. For example, each R11may be independently selected from a -OH, -NH2, -R110, -CO-R111, -OR110, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the same nitrogen atom 15 may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms, and wherein each R111is independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Typically, where the saturated spiro bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or a single 20 oxo (=O) group and / or one or two groups R11, wherein each R11is independently selected from a -NH2, -R110, -CO-R111, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 25 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms, and wherein each R111is independently selected from a C1-C3 alkyl, C1- C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically, where the saturated spiro bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or a single oxo (=O) group and / or a single group selected 30 from -R110or -CO-R111, wherein if present -R110or -CO-R111is directly attached to a ring nitrogen atom of the saturated spiro bicyclic heterocyclic group, wherein R110is selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, and wherein R111is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Typically, 35 where -R110or -CO-R111is directly attached to a ring nitrogen atom of the saturated spiro bicyclic heterocyclic group, the ring nitrogen atom is a ring nitrogen atom of the second ring system. - 27 - In one embodiment, R1has the formula: wherein: X12is O or NR12; 5 m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; and q is 0, 1, 2, 3 or 4; provided that: 10 m + n = 3 or 4; p + q = 3 or 4; when m = 0, q is 1, 2, 3 or 4 and p is 1, 2, 3 or 4; when n = 0, q is 1, 2, 3 or 4 and p is 1, 2, 3 or 4; when p = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and 15 when q = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and wherein: r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 20 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group, wherein R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each R13is independently selected from a methyl or fluoromethyl group. 25 As will be understood, in such an embodiment the compound is a compound of Formula (Ie): - 28 - Formula (Ie) wherein X1-X4, X12, A1-A6, Q1, R2, R3, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 5 Typically in such an embodiment, m is 1 or 2 and n is 1 or 2. Typically in such an embodiment, p is 0, 1 or 2 and q is 1, 2 or 3. More typically, p is 0, 1 or 2 and q is 2 or 3. 10 Typically in such an embodiment, r is 0 and s is 0. Typically in such an embodiment, R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1- C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl 15 group. More typically, R12is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically, R12is hydrogen or a methyl or fluoromethyl group. For example, R1may have a formula selected from: 20 In a particular example of such an embodiment, m is 1, n is 1, p is 1 or 2, q is 1, r is 0 and s is 0. Typically in such an example, R12is hydrogen. 25 - 29 - In another embodiment, R1has the formula: wherein: m is 0, 1, 2, 3 or 4; 5 n is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: m + n = 3 or 4; 10 p + q = 2 or 3; when m = 0, p is 1, 2 or 3; when n = 0, p is 1, 2 or 3; and when p = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and wherein: 15 r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; and each R13is independently selected from a methyl or fluoromethyl group. 20 As will be understood, in such an embodiment the compound is a compound of Formula (If): Formula (If) 25 wherein X1-X4, A1-A6, Q1, R2, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). - 30 - Typically in such an embodiment, m is 1 or 2 and n is 1 or 2. More typically, m is 2 and n is 2. 5 Typically in such an embodiment, p is 1 or 2 and q is 1 or 2. More typically, p is 1 and q is 1. Typically in such an embodiment, r is 0 and s is 0. 10 Typically in such an embodiment, R12is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically, R12is hydrogen or a methyl or fluoromethyl group. More typically still, R12is hydrogen. For example, R1may have the formula:15 .In another embodiment, R1is a non-aromatic bridged bicyclic heterocyclic group, wherein the non-aromatic bridged bicyclic heterocyclic group may optionally be substituted with one or more groups each independently selected from a halo, oxo 20 (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C8 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one, two or three heteroatoms 25 each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. Typically in such an embodiment, the non-aromatic bridged bicyclic heterocyclic group is saturated. Typically, the non-aromatic bridged 30 bicyclic heterocyclic group contains a ring nitrogen atom that is directly attached to the remainder of the molecule. Typically, the non-aromatic bridged bicyclic heterocyclic group contains at least one further ring nitrogen or a ring oxygen atom. More typically, the non-aromatic bridged bicyclic heterocyclic group contains at least one further ring nitrogen atom. Typically, the non-aromatic bridged bicyclic 35 heterocyclic group contains no more than three ring heteroatoms. More typically, the - 31 - non-aromatic bridged bicyclic heterocyclic group contains no more than two ring heteroatoms. Typically, where R1is a non-aromatic bridged bicyclic heterocyclic group, the group is a 7- to 9-membered bridged bicyclic group. More typically, the group is a 7- or 8-membered bridged bicyclic group. Where the non-aromatic bridged bicyclic 5 heterocyclic group is substituted, typically it is substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may 10 optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More typically, where the non-aromatic bridged bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or a single oxo (=O) group, and / or 15 one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group 20 may optionally include a single heteroatom selected from N and O in its carbon skeleton. For example, each R11may be independently selected from a -OH, -NH2, -R110, -CO-R111, -OR110, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the 25 same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no more than four carbon atoms, and wherein each R111is independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. 30 In another embodiment, R1is a saturated bridged bicyclic heterocyclic group, wherein the saturated bridged bicyclic heterocyclic group comprises at least one ring nitrogen atom, wherein the saturated bridged bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11, wherein each R11is independently selected from -OH, 35 -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated - 32 - hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. Typically, the ring nitrogen atom of the saturated bridged bicyclic heterocyclic group is directly attached to the remainder of the molecule. Typically, the saturated bridged bicyclic heterocyclic group contains at 5 least one further ring nitrogen or a ring oxygen atom. More typically, the saturated bridged bicyclic heterocyclic group contains at least one further ring nitrogen atom. Typically, the saturated bridged bicyclic heterocyclic group contains no more than three ring heteroatoms. More typically, the saturated bridged bicyclic heterocyclic group contains no more than two ring heteroatoms. Typically, where R1is a saturated 10 bridged bicyclic heterocyclic group, the group is a 7- to 9-membered bridged bicyclic group. More typically, the group is a 7- or 8-membered bridged bicyclic group. Where the saturated bridged bicyclic heterocyclic group is substituted, typically it is substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a 15 C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon 20 skeleton. For example, each R11may be independently selected from a -OH, -NH2, -R110, -CO-R111, -OR110, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene 25 group, provided that the group -N(R110)2 contains no more than four carbon atoms, and wherein each R111is independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Typically, where the saturated bridged bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one or two groups R11, wherein each R11is 30 independently selected from a -NH2, -R110, -CO-R111, -NHR110or -N(R110)2 group, wherein each R110is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R110attached to the same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group, provided that the group -N(R110)2 contains no 35 more than four carbon atoms, and wherein each R111is independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically, where the saturated bridged bicyclic heterocyclic group is substituted, it is substituted with one or more fluoro groups and / or a single oxo (=O) group and / or a single group - 33 - selected from -R110or -CO-R111, wherein if present -R110or -CO-R111is directly attached to a ring nitrogen atom of the saturated bridged bicyclic heterocyclic group, wherein R110is selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, and wherein R1115 is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. In one embodiment, R1has the formula: wherein: 10 w is 1 or 2; X12is O or NR12; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group, wherein R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 15 fluorocyclopropyl group; one R14and one R15together form a -CH2- or -CH2CH2- group; and each remaining R14and R15is hydrogen. As will be understood, in such an embodiment the compound is a compound of 20 Formula (Ig): Formula (Ig) wherein X1-X4, X12, A1-A6, Q1, R2, R3, R14, R15and w are as defined in accordance with Formula (I). 25 Typically in such an embodiment, w is 1. - 34 - Typically in such an embodiment, X12is NR12. Typically in such an embodiment, R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1- 5 C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. More typically, R12is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically still, R12is hydrogen or a methyl or fluoromethyl group. Yet more typically, R12is a methyl or fluoromethyl group. 10 Typically in such an embodiment, one R14and one R15together form a -CH2CH2- group. For example, R1may have the formula: . 15 As stated in accordance with the first aspect of the invention, R2and R3are each independently selected from hydrogen or a C1-C12 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the saturated hydrocarbyl group may 20 optionally be substituted with one or more halo, oxo (=O) and / or -NO2 groups, wherein the saturated hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and 25 =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, or R2and R3together with the nitrogen atom to which they are attached form a 3- to 12-membered saturated cyclic group, wherein the saturated cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C6saturated 30 hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more halo, oxo (=O) and / or -NO2 groups, wherein the saturated hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and 35 wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. - 35 - Typically the atom of any saturated hydrocarbyl group or saturated cyclic group of R2and / or R3that is directly attached to the nitrogen atom of N-R3is a carbon atom. More typically, the atom of any saturated hydrocarbyl group or saturated cyclic group of R25 and / or R3that is directly attached to the nitrogen atom of N-R3is a carbon atom that is not substituted with an oxo (=O) group. Most typically, the atom of any saturated hydrocarbyl group or saturated cyclic group of R2and / or R3that is directly attached to the nitrogen atom of N-R3is a sp3hybridised carbon atom. 10 In one embodiment of the first aspect of the invention, R2and R3are each independently selected from hydrogen or a C1-C12 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more halo, oxo (=O) and / or -NO2 groups, 15 wherein the saturated hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. For example, R2may be 20 selected from hydrogen or a C1-C12 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more halo, oxo (=O) and / or -NO2 groups, wherein the saturated hydrocarbyl group may optionally include one or more heteroatoms each 25 independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, and R3may be selected from hydrogen or a C1-C4 alkyl, C1-C4 haloalkyl, C3-C4 cycloalkyl, C3-C4 halocycloalkyl, cyclopropylmethyl 30 or fluorocyclopropylmethyl group. Typically in such an embodiment, R2and R3are each independently selected from hydrogen or a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or two cyclic groups, 35 wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or oxo (=O) groups, wherein the saturated hydrocarbyl group may optionally include one, two, three or four heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated - 36 - hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. For example, R2may be a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be 5 or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or oxo (=O) groups, wherein the saturated hydrocarbyl group may optionally include one, two, three or four heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may optionally be 10 substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, and R3may be selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. 15 More typically in such an embodiment, R2and R3are each independently selected from hydrogen or a C1-C8 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or oxo (=O) groups, and wherein the saturated hydrocarbyl group 20 may optionally include one, two, three or four heteroatoms each independently selected from N and O in its carbon skeleton. For example, R2may be a C1-C8 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro 25 and / or oxo (=O) groups, and wherein the saturated hydrocarbyl group may optionally include one, two, three or four heteroatoms each independently selected from N and O in its carbon skeleton, and R3may be selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. 30 Typically in the above embodiments, R3is selected from hydrogen or a C1-C4 alkyl, C1- C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group. More typically, R3is selected from hydrogen or a methyl, ethyl, fluoromethyl or fluoroethyl group. More typically still, R3is selected from hydrogen or a methyl or fluoromethyl group. Most 35 typically, R3is hydrogen. Typically in the above embodiments, the hydrocarbyl group of R2includes at least one heteroatom selected from N, O and S in its carbon skeleton. More typically, the - 37 - hydrocarbyl group of R2includes at least one heteroatom selected from N and O in its carbon skeleton. For example, the hydrocarbyl group of R2may comprise a primary, secondary or tertiary amine, wherein the nitrogen atom of the primary, secondary or tertiary amine is not directly attached to a sp2hybridised carbon atom. Accordingly, in 5 one embodiment R2is a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one nitrogen atom in its carbon skeleton, wherein 10 said nitrogen atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3may be selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3- C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. Typically in 15 such an embodiment, R2is a C1-C8 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one nitrogen atom in its carbon 20 skeleton, wherein said nitrogen atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group. Typically in such an embodiment, R3is 25 selected from hydrogen or a methyl, ethyl, fluoromethyl or fluoroethyl group. More typically, R3is selected from hydrogen or a methyl or fluoromethyl group. More typically still, R3is hydrogen. In one aspect of the above embodiments, the hydrocarbyl group of R2includes at least 30 one nitrogen atom in its carbon skeleton, wherein said nitrogen atom is a nitrogen atom of a tertiary amine and wherein said nitrogen atom is not directly attached to a sp2hybridised carbon atom. For example, R2may be a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be branched, or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be 35 substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one nitrogen atom in its carbon skeleton, wherein said nitrogen atom is a nitrogen atom of a tertiary amine, wherein said nitrogen atom is not directly attached to a sp2hybridised carbon atom, and - 38 - wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3may be selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3- C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. Typically in 5 such an embodiment, R2is a C1-C8 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one nitrogen atom in its carbon skeleton, wherein said nitrogen 10 atom is a nitrogen atom of a tertiary amine, wherein said nitrogen atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group. Typically 15 in such an embodiment, R3is selected from hydrogen or a methyl, ethyl, fluoromethyl or fluoroethyl group. More typically, R3is selected from hydrogen or a methyl or fluoromethyl group. More typically still, R3is hydrogen. Alternatively, the hydrocarbyl group of R2may include at least one oxygen atom in its 20 carbon skeleton, wherein said oxygen atom is not directly attached to a sp2hybridised carbon atom. For example, R2may be a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, 25 wherein the saturated hydrocarbyl group includes at least one oxygen atom in its carbon skeleton, wherein said oxygen atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3may be selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3- 30 C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. Typically in such an embodiment, R2is a C1-C8 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, 35 wherein the saturated hydrocarbyl group includes at least one oxygen atom in its carbon skeleton, wherein said oxygen atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon - 39 - skeleton, and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group. Typically in such an embodiment, R3is selected from hydrogen or a methyl, ethyl, fluoromethyl or fluoroethyl group. More typically, R3is selected from hydrogen or a methyl or fluoromethyl group. More 5 typically still, R3is hydrogen. In one aspect of the above embodiments, the hydrocarbyl group of R2may include at least one oxygen atom in its carbon skeleton, wherein said oxygen atom is an oxygen atom of an ether and wherein said oxygen atom is not directly attached to a sp210 hybridised carbon atom. For example, R2may be a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one oxygen atom in 15 its carbon skeleton, wherein said oxygen atom is an oxygen atom of an ether, wherein said oxygen atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3may be selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3- 20 C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. Typically in such an embodiment, R2is a C1-C8 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the 25 saturated hydrocarbyl group includes at least one oxygen atom in its carbon skeleton, wherein said oxygen atom is an oxygen atom of an ether, wherein said oxygen atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3is selected from 30 hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group. Typically in such an embodiment, R3is selected from hydrogen or a methyl, ethyl, fluoromethyl or fluoroethyl group. More typically, R3is selected from hydrogen or a methyl or fluoromethyl group. More typically still, R3is hydrogen. 35 Alternatively still, the hydrocarbyl group of R2may include at least one sulphur atom in its carbon skeleton, wherein said sulphur atom is not directly attached to a sp2hybridised carbon atom. For example, R2may be a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, - 40 - or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one sulphur atom in its carbon skeleton, wherein said sulphur atom is not directly attached to a sp25 hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3may be selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. Typically in such an embodiment, R2is a C1-C8 10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one sulphur atom in its carbon skeleton, wherein said sulphur atom is not 15 directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group. Typically in such an embodiment, R3is selected from hydrogen or a methyl, 20 ethyl, fluoromethyl or fluoroethyl group. More typically, R3is selected from hydrogen or a methyl or fluoromethyl group. More typically still, R3is hydrogen. In one aspect of the above embodiments, the hydrocarbyl group of R2may include at least one sulphur atom in its carbon skeleton, wherein said sulphur atom is a sulphur 25 atom of a thioether and wherein said sulphur atom is not directly attached to a sp2hybridised carbon atom. For example, R2may be a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) 30 groups, wherein the saturated hydrocarbyl group includes at least one sulphur atom in its carbon skeleton, wherein said sulphur atom is a sulphur atom of a thioether, wherein said sulphur atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, 35 and R3may be selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. Typically in such an embodiment, R2is a C1-C8 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or - 41 - include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one sulphur atom in its carbon skeleton, wherein said sulphur atom is a sulphur atom of a thioether, wherein said 5 sulphur atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton, and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group. Typically in such an embodiment, R3is selected from hydrogen 10 or a methyl, ethyl, fluoromethyl or fluoroethyl group. More typically, R3is selected from hydrogen or a methyl or fluoromethyl group. More typically still, R3is hydrogen. In one embodiment, the group -CONR2R3is acyclic, i.e. the group -CONR2R3does not contain any cyclic moieties or groups. 15 In other embodiments, the group -CONR2R3contains at least one cyclic moiety or group. For example, in one embodiment, R2and R3together with the nitrogen atom to which 20 they are attached form a 3- to 12-membered saturated cyclic group, wherein the saturated cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single 25 cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more halo, oxo (=O) and / or -NO2 groups, wherein the saturated hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or 30 two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. As will be understood, where R2and R3together with the nitrogen atom to which they are attached form a 3- to 12-membered saturated cyclic group, the resultant cyclic 35 group is a saturated heterocyclic group. Typically in such an embodiment, R2and R3together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated monocyclic group or a 6- to 10- - 42 - membered saturated bicyclic group, wherein the monocyclic or the bicyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, oxo (=O), -OH, -NH2 or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or 5 include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or oxo (=O) groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More typically in such an embodiment, R2and R3together with the nitrogen atom to which they are attached 10 form a 4- to 7-membered saturated monocyclic group or a 6- to 10-membered saturated bicyclic group, wherein the monocyclic or the bicyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, oxo (=O), -OH, -NH2 or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a 15 single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. 20 In one embodiment, R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group, wherein the azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R24, wherein each R24is independently selected from -OH, -NH2, or a C1-C4 25 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon 30 skeleton. Typically in such an embodiment, R2and R3together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl or piperidinyl group. In one embodiment, R2and R3together with the nitrogen atom to which they are35 attached form a 6- or 7-membered saturated monocyclic group or a 7- to 10- membered saturated bicyclic group, wherein the monocyclic group or the bicyclic group includes at least one further ring nitrogen atom, wherein said further ring nitrogen atom is not directly attached to a sp2hybridised carbon atom, and wherein - 43 - the monocyclic group or the bicyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R24, wherein each R24is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained 5 or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. Typically in such an embodiment, R2and R3together with the nitrogen atom to which they are attached 10 form a 6- or 7-membered saturated monocyclic group or a 8- or 9-membered saturated fused bicyclic group. More typically in such an embodiment, R2and R3together with the nitrogen atom to which they are attached form a 6- or 7-membered saturated monocyclic group. 15 In one aspect of the above embodiment, the further ring nitrogen atom is substituted with a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group 20 may optionally include a single heteroatom selected from N and O in its carbon skeleton. For example, R2and R3may together with the nitrogen atom to which they are attached form a 6- or 7-membered saturated monocyclic group or a 7- to 10- membered saturated bicyclic group, wherein the monocyclic group or the bicyclic group includes at least one further ring nitrogen atom, wherein said further ring 25 nitrogen atom is substituted with a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom 30 selected from N and O in its carbon skeleton, wherein said further ring nitrogen atom is not directly attached to a sp2hybridised carbon atom, and wherein the monocyclic group or the bicyclic group may optionally be further substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one group R24, wherein R24is selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the 35 saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom - 44 - selected from N and O in its carbon skeleton. Typically in such an aspect, said further ring nitrogen atom is substituted with a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. More typically in such an aspect, said further ring nitrogen atom is substituted with a C1-C4 5 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group. Typically in such an aspect, R2and R3together with the nitrogen atom to which they are attached form a 6- or 7-membered saturated monocyclic group or a 8- or 9-membered saturated fused bicyclic group. More typically in such an aspect, R2and R3together with the nitrogen atom to which they are attached form a 6- or 7-membered saturated 10 monocyclic group. In another embodiment, R2and R3together with the nitrogen atom to which they are attached form a 6- or 7-membered saturated monocyclic group or a 7- to 10- membered saturated bicyclic group, wherein the monocyclic group or the bicyclic 15 group includes at least one ring oxygen atom, wherein said ring oxygen atom is not directly attached to a sp2hybridised carbon atom, and wherein the monocyclic group or the bicyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R24, wherein each R24is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, 20 wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. Typically in such an 25 embodiment, R2and R3together with the nitrogen atom to which they are attached form a 6- or 7-membered saturated monocyclic group. In yet another embodiment, R2and R3together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated monocyclic group or a 7- to 10- 30 membered saturated bicyclic group, wherein the monocyclic group or the bicyclic group is substituted with a -N(R25)2 group, wherein each R25is independently selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or wherein any two R25together form a C2-C4 allkylene or C2-C4 fluoroallkylene group, and wherein 35 the monocyclic group or the bicyclic group may optionally be further substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R24, wherein each R24is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be - 45 - straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon 5 skeleton. Typically in such an embodiment, each R25is independently selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group, such as a methyl, fluoromethyl, ethyl or fluoroethyl group, or any two R25together form a C2-C4 allkylene or C2-C4 fluoroallkylene group. Typically in such an embodiment, R2and R3together with the nitrogen atom to which they are attached 10 form a 4- to 7-membered saturated monocyclic group. In one aspect of such an embodiment, each R25is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R25together form a C2-C4 allkylene or C2-C4 15 fluoroallkylene group. More typically, each R25is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group, such as a methyl, fluoromethyl, ethyl or fluoroethyl group, or any two R25together form a C2-C4 allkylene or C2-C4 fluoroallkylene group. 20 In a further embodiment, R2and R3together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated monocyclic group or a 7- to 10- membered saturated bicyclic group, wherein the monocyclic group or the bicyclic group is substituted with a -OR25group, wherein R25is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, 25 cyclopropylmethyl or fluorocyclopropylmethyl group, and wherein the monocyclic group or the bicyclic group may optionally be further substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R24, wherein each R24is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained 30 or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. Typically in such an embodiment, R25is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 35 cycloalkyl or C3-C4 fluorocycloalkyl group. Typically in such an embodiment, R2and R3together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated monocyclic group. - 46 - In one aspect of such an embodiment, R25is selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group. More typically, R25is selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group, such as a methyl, fluoromethyl, ethyl or fluoroethyl group. 5 Typically in the above embodiments, each R24is independently selected from a -OH, -NH2, -R240, -OR240, -NHR240or -N(R240)2 group, wherein each R240is independently selected from a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group (more typically a C1-C4 alkyl, C1- 10 C4 fluoroalkyl, C3-C4 cycloalkyl or C3-C4 fluorocycloalkyl group) provided that the group -N(R240)2 contains no more than four carbon atoms, or any two R240attached to the same nitrogen atom may together form a C2-C4 alkylene or a C2-C4 fluoroalkylene group. More typically, each R24is independently selected from a -NH2, -R240, -NHR240or -N(R240)2 group, wherein each R240is independently selected from a methyl or 15 fluoromethyl group. More typically still, each R24is independently selected from a methyl or fluoromethyl group. Typically in the above embodiments, the group -CONR2R3contains no more than 12 carbon atoms. More typically, the group -CONR2R3contains no more than 10 carbon 20 atoms. More typically still, the group -CONR2R3contains no more than 8 carbon atoms. In one embodiment: R2is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 25 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; or 30 R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group, any of which may optionally be fluoro-substituted. Typically in such an embodiment: 35 R2is selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl or cyclopropylmethyl group; and R3is selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl or cyclopropylmethyl group; or - 47 - R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl or piperidinyl group. More typically in such an embodiment: 5 R2is selected from hydrogen or a methyl or ethyl group; and R3is selected from hydrogen or a methyl or ethyl group; or R2and R3together with the nitrogen atom to which they are attached form a pyrrolidinyl group. 10 For example, -CONR2R3may have the formula -CONH2, -CONHMe, -CON(Me)2, . In one aspect of such an embodiment, R3is hydrogen. For example, -CONR2R3may have the formula -CONH2, -CONHMe or -CONHEt. 15 In a particular embodiment, -CONR2R3has the formula -CONH2. As will be understood, in such an embodiment the compound is a compound of Formula (II): Formula (II) 20 wherein R1, X1-X4, A1-A6and Q1are as defined in accordance with Formula (I). In another embodiment, -CONR2R3has the formula: wherein: 25 Q2is O, S or NR22; - 48 - L2is a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes a single heteroatom independently selected from O and N in its carbon skeleton, wherein L2has a chain length of from 2 to 6 atoms, and wherein L2may optionally be substituted with one or more fluoro groups and / or one or two oxo 5 (=O) groups and / or one, two, three or four groups RL2; R3is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and wherein the 10 saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; R21is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted 15 with one or more fluoro groups and / or one or two oxo (=O) groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; R22is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single 20 cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or two 25 groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; each RL2is independently selected from a methyl or fluoromethyl group; or R3and any RL2may, together with the atoms to which they are attached, form a 3- to 7-membered saturated monocyclic heterocyclic group, wherein the 3- to 30 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four groups RL3; or R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic group, wherein the 6- or 7- 35 membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four groups RL3; - 49 - or any two RL2may, together with the atom or atoms to which they are attached, form a 3- to 7-membered saturated monocyclic group, wherein the 3- to 7- membered saturated monocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four 5 groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 3- to 7-membered saturated monocyclic heterocyclic group, wherein the 3- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, 10 three or four groups RL3; or R21and R22may, together with the nitrogen atom to which they are attached form a 3- to 7-membered saturated monocyclic heterocyclic group, wherein the 3- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, 15 three or four groups RL3; or R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or 20 one, two, three or four groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or 25 one, two, three or four groups RL3; or R3, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10- membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three 30 or four groups RL3; or any two RL2and R21may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or 35 one, two, three or four groups RL3; or any RL2, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be - 50 - substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-Q2-R21contains no more than 12 carbon 5 atoms. As will be understood, in such an embodiment the compound is a compound of Formula (III): 10 Formula (III) wherein R1, X1-X4, A1-A6, Q1, Q2, R3, L2and R21are as defined in accordance with Formula (I). As will also be understood, where any two or more groups together with the atom or 15 atoms to which they are attached form a cyclic group, the two or more groups may together form a single ring atom or more than one ring atom of the cyclic group. For instance, in the above embodiment where two RL2together with the atom or atoms to which they are attached form a 3-membered saturated monocyclic group, the two RL2may for example together form a -CH2- or a -CH2CH2- group. Thus, by way of example 20 it may be envisaged that L2may have the formula: . Typically in such an embodiment: L2is a straight-chained alkylene group, wherein the straight-chained alkylene 25 group optionally includes a single heteroatom independently selected from O and N in its carbon skeleton, wherein L2has a chain length of from 2 to 5 atoms, and wherein L2may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four groups RL2; and where R22is selected from a C1-C6 saturated hydrocarbyl group, wherein the 30 saturated hydrocarbyl group may be straight-chained or branched, or be or include a - 51 - single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N, O and S in its carbon skeleton, 5 wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, R22is a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl 10 group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. 15 Typically, the group -CO-N(R3)-L2-Q2-R21contains no more than 10 carbon atoms. More typically, the group -CO-N(R3)-L2-Q2-R21contains no more than 8 carbon atoms. Typically in such an embodiment, Q2is O or NR22. More typically, Q2is NR22. 20 Typically, the atom of the alkylene group of L2that is directly attached to Q2is a carbon atom that is not substituted with an oxo (=O) group. Typically, the atom of the alkylene group of L2that is directly attached to the nitrogen atom of N-R3is a carbon atom. More typically, the atom of the alkylene group of L2that is directly attached to the nitrogen atom of N-R3is a carbon atom that is not substituted with an oxo (=O) 25 group. For example, in one embodiment L2is a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes a single heteroatom independently selected from O and N in its carbon skeleton, wherein L2has a chain length of from 2 to 6 atoms, and wherein L2may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four 30 groups RL2, provided that the carbon atom of the alkylene group that is directly attached to Q2is not substituted with an oxo (=O) group. Typically in such an embodiment, L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the 35 -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon - 52 - atom of the alkylene or the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group that is directly attached to Q2is not substituted with an oxo (=O) group. Typically, the carbon atom of the alkylene, the 5 -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group of L2that is directly attached to the nitrogen atom of N-R3is not substituted with an oxo (=O) group. In a further embodiment, L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or 10 more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon atom of the alkylene group that is directly attached to Q2is not substituted with an oxo (=O) group. Typically in such an embodiment, the carbon atom of the alkylene group of L2that is directly attached to the nitrogen atom of N-R3is not substituted with an oxo (=O) group. 15 More typically in such embodiments, L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the 20 -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2. For example, L2may be a C2-C4 straight- chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2. More typically still in such an 25 embodiment, L2is a C2-C3 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2. Typically where -CONR2R3has the formula -CO-N(R3)-L2-Q2-R21, the atom of R3that is 30 directly attached to the nitrogen atom of N-R3is a hydrogen atom or a carbon atom. More typically, the atom of R3that is directly attached to the nitrogen atom of N-R3is a hydrogen atom or a carbon atom that is not substituted with an oxo (=O) group. In one embodiment, R3is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein 35 the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two - 53 - heteroatoms each independently selected from N and O in its carbon skeleton. Typically in such an embodiment, the atom of the saturated hydrocarbyl group of R3that is directly attached to the nitrogen atom of N-R3is a carbon atom. More typically, the atom of the saturated hydrocarbyl group of R3that is directly attached to the 5 nitrogen atom of N-R3is a carbon atom that is not substituted with an oxo (=O) group. More typically in such an embodiment, R3is hydrogen or a C1-C4 alkyl group, wherein the alkyl group may be straight-chained or branched, or be or include a single cyclic group, and wherein the alkyl group may optionally be substituted with one or more fluoro groups. More typically still, R3is hydrogen or a C1-C3 alkyl, C1-C3 10 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Yet more typically, R3is hydrogen or a methyl, ethyl, fluoromethyl or fluoroethyl group. Most typically in such an embodiment, R3is hydrogen. Typically, the atom of R21that is directly attached to Q2is a hydrogen atom or a 15 carbon atom that is not substituted with an oxo (=O) group. For example, in one embodiment R21is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and 20 wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R21that is directly attached to Q2is a carbon atom that is not substituted with an oxo (=O) group. Typically in such an embodiment, R21is hydrogen or a C1-C4 alkyl group, wherein the 25 alkyl group may be straight-chained or branched, or be or include a single cyclic group, and wherein the alkyl group may optionally be substituted with one or more fluoro groups. More typically in such an embodiment, R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. 30 In one embodiment, the atom of R22that is directly attached to the nitrogen atom of -NR21R22is a hydrogen atom or a carbon atom that is not substituted with an oxo (=O) group. For example, in one embodiment R22is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl 35 group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R22that is - 54 - directly attached to the nitrogen atom of -NR21R22is a carbon atom that is not substituted with an oxo (=O) group. Typically in such an embodiment, R22is hydrogen or a C1-C4 alkyl group, wherein the alkyl group may be straight-chained or branched, or be or include a single cyclic group, and wherein the alkyl group may optionally be 5 substituted with one or more fluoro groups. More typically in such an embodiment, R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. In another embodiment, the atom of R22that is directly attached to the nitrogen atom of -NR21R22is the carbon atom of a carbonyl group or the sulphur atom of a -SO- or 10 -SO2- group. For example, R22may be selected from a -CO-R220, -SO-R220or -SO2-R220group, wherein R220is a C1-C5 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the 15 saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. Typically in such an embodiment, the atom of R220that is directly attached to the carbon atom of the -CO-R220group or that is directly attached to the sulphur atom of the SO-R220or -SO2-R220group is a sp3hybridised carbon atom. More typically in such an 20 embodiment, R220is a C1-C4 alkyl group, wherein the alkyl group may be straight- chained or branched, or be or include a single cyclic group, and wherein the alkyl group may optionally be substituted with one or more fluoro groups. More typically still in such an embodiment, R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. 25 In one aspect, where -CONR2R3has the formula -CO-N(R3)-L2-Q2-R21, R21is not hydrogen and, if present, R22is not hydrogen. In one embodiment, R3and any RL2may, together with the atoms to which they are 30 attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, such as an azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group, wherein the 4- to 7- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3. Typically in such an embodiment, the two ring atoms of the saturated 35 monocyclic heterocyclic group that are directly attached to the nitrogen atom of N-R3are both carbon atoms that are not substituted with an oxo (=O) group. More typically in such an embodiment, R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, - 55 - wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3. Typically, where R3and R21together with the atoms to which they are attached form a 5 6- or 7-membered saturated monocyclic heterocyclic group, the two ring atoms of the 6- or 7-membered saturated monocyclic heterocyclic group that are directly attached to Q2are both carbon atoms that are not substituted with an oxo (=O) group. For example, R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic group, such as a morpholinyl, 10 piperazinyl or diazepanyl group, wherein the 6- or 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 6- or 7-membered saturated monocyclic heterocyclic group that are directly attached to Q2are both carbon atoms that are not substituted 15 with an oxo (=O) group. Typically in such an embodiment, the two ring atoms of the saturated monocyclic heterocyclic group that are directly attached to the nitrogen atom of N-R3are both carbon atoms that are not substituted with an oxo (=O) group. More typically in such an embodiment, R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic 20 group, wherein the 6- or 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3. In one embodiment, each RL2is independently selected from a methyl or a fluoromethyl group, or any two RL2may, together with the atom or atoms to which 25 they are attached, form a C3-C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3. For example, each RL2may be independently selected from a methyl or a fluoromethyl 30 group, or any two RL2may, together with the carbon atom or carbon atoms to which they are attached, form a C3-C6 cycloalkylene group, wherein the C3-C6 cycloalkylene group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3. Typically in such an embodiment, each RL2is independently selected from a methyl or a fluoromethyl 35 group, or any two RL2may, together with the atom or atoms to which they are attached, form a C3-C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro - 56 - groups and / or one or two groups RL3. For example, each RL2may be independently selected from a methyl or a fluoromethyl group, or any two RL2may, together with the carbon atom or carbon atoms to which they are attached, form a C3-C5 cycloalkylene group, wherein the C3-C5 cycloalkylene group may optionally be substituted with one 5 or more fluoro groups and / or one or two groups RL3. More typically in such an embodiment, each RL2is independently selected from a methyl or a fluoromethyl group. Typically, where any RL2and R21together with the atoms to which they are attached 10 form a 3- to 7-membered saturated monocyclic heterocyclic group, the two ring atoms of the 3- to 7-membered saturated monocyclic heterocyclic group that are directly attached to Q2are both carbon atoms that are not substituted with an oxo (=O) group. For example, any RL2and R21may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, such as15 an azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group, wherein the 4- to 7- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 4- to 7-membered saturated monocyclic heterocyclic group that are directly attached to Q2are both carbon atoms 20 that are not substituted with an oxo (=O) group. Typically in such an embodiment, any RL2and R21may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3. 25 Typically, where R21and R22together with the nitrogen atom to which they are attached form a 3- to 7-membered saturated monocyclic heterocyclic group, the two ring atoms of the 3- to 7-membered saturated monocyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not 30 substituted with an oxo (=O) group. For example, R21and R22may together with the nitrogen atom to which they are attached form a 3- to 6-membered saturated monocyclic heterocyclic group, such as an aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro 35 groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 3- to 6-membered saturated monocyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group. Typically in such an - 57 - embodiment, R21and R22may together with the nitrogen atom to which they are attached form a 3- to 5-membered saturated monocyclic heterocyclic group, such as an aziridinyl, azetidinyl, or pyrrolidinyl group, wherein the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or 5 more fluoro groups and / or one or two groups RL3. In one embodiment, R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally 10 be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3. Typically in such an embodiment, the two ring atoms of the saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of N-R3are both carbon atoms that are not substituted with an oxo (=O) group. In one aspect of such an embodiment, R3and any two RL2may, together 15 with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3. 20 Typically, where R3, R21and any RL2together with the atoms to which they are attached form a 7- to 10-membered saturated bicyclic heterocyclic group, the two ring atoms of the 7- to 10-membered saturated bicyclic heterocyclic group that are directly attached to Q2are both carbon atoms that are not substituted with an oxo (=O) group. For example, R3, R21and any RL2may, together with the atoms to which they 25 are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to Q2are 30 both carbon atoms that are not substituted with an oxo (=O) group. Typically in such an embodiment, the two ring atoms of the saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of N-R3are both carbon atoms that are not substituted with an oxo (=O) group. In one aspect of such an embodiment, R3, R21and any RL2may, together with the atoms to which they are attached, form a 8- to35 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10- membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3. - 58 - Typically, where R3, R21and R22together with the atoms to which they are attached form a 7- to 10-membered saturated bicyclic heterocyclic group, the three ring atoms of the 7- to 10-membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are all carbon atoms that are not 5 substituted with an oxo (=O) group. For example, R3, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the three ring 10 atoms of the 7- to 10-membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are all carbon atoms that are not substituted with an oxo (=O) group. Typically in such an embodiment, the two ring atoms of the saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of N-R3are both carbon atoms that are not substituted with an oxo 15 (=O) group. In one aspect of such an embodiment, R3, R21and R22may, together with the atoms to which they are attached, form a 9- or 10-membered saturated fused bicyclic heterocyclic group, wherein the 9- or 10-membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3. 20 Typically, where any two RL2and R21together with the atoms to which they are attached form a 7- to 10-membered saturated bicyclic heterocyclic group, the two ring atoms of the 7- to 10-membered saturated bicyclic heterocyclic group that are directly attached to Q2are both carbon atoms that are not substituted with an oxo (=O) 25 group. For example, any two RL2and R21may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- 30 membered saturated bicyclic heterocyclic group that are directly attached to Q2are both carbon atoms that are not substituted with an oxo (=O) group. In one aspect of such an embodiment, any two RL2and R21may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may 35 optionally be substituted with one or more fluoro groups and / or one or two groups RL3. Typically, where any RL2, R21and R22together with the atoms to which they are attached form a 7- to 10-membered saturated bicyclic heterocyclic group, the three - 59 - ring atoms of the 7- to 10-membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are all carbon atoms that are not substituted with an oxo (=O) group. For example, any RL2, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated 5 bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the three ring atoms of the 7- to 10-membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are all carbon atoms 10 that are not substituted with an oxo (=O) group. In one aspect of such an embodiment, any RL2, R21and R22may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3. 15 Accordingly, in a particular embodiment, where Q2is NR22, -CONR2R3has the formula: wherein: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, 20 -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or a single 25 oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon atom of the alkylene or the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group that is directly attached to the nitrogen atom of -NR21R22is not substituted with an oxo (=O) group; 30 R3is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each 35 independently selected from N and O in its carbon skeleton, provided that the atom of - 60 - any saturated hydrocarbyl group of R3that is directly attached to the nitrogen atom of N-R3is a carbon atom; R21is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single 5 cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R21that is directly attached to the nitrogen atom 10 of -NR21R22is a carbon atom that is not substituted with an oxo (=O) group; and R22is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the 15 saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R22that is directly attached to the nitrogen atom of -NR21R22is a carbon atom that is not substituted with an oxo (=O) group; or R22is selected from a -CO-R220, -SO-R220or -SO2-R220group; 20 R220is a C1-C5 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently 25 selected from N and O in its carbon skeleton; each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group 30 may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted 35 with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic group, wherein the 6- or 7- - 61 - membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 6- or 7-membered saturated monocyclic heterocyclic group that are directly attached to the nitrogen atom of 5 -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or any RL2and R21may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three 10 or four groups RL3, provided that the two ring atoms of the 4- to 7-membered saturated monocyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or R21and R22may, together with the nitrogen atom to which they are 15 attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 3- to 6- membered saturated monocyclic heterocyclic group that are directly attached to the 20 nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be 25 substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be 30 substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; 35 or R3, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10- membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or - 62 - four groups RL3, provided that the three ring atoms of the 7- to 10-membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are all carbon atoms that are not substituted with an oxo (=O) group; or any two RL2and R21may, together with the atoms to which they are 5 attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the 10 nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or any RL2, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be 15 substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the three ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are all carbon atoms that are not substituted with an oxo (=O) group; and 20 each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 12 carbon atoms. As will be understood, in such an embodiment the compound is a compound of 25 Formula (IV): Formula (IV) wherein R1, X1-X4, A1-A6, Q1, R3, L2, R21and R22are as defined in accordance with Formula (I). 30 In one aspect of such an embodiment: - 63 - L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon atom of the alkylene group that is directly attached to the nitrogen atom of -NR21R22is not 5 substituted with an oxo (=O) group; R22is not selected from a -CO-R220, -SO-R220or -SO2-R220group; and each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the carbon atom or carbon atoms to which they are attached, form a C3-C6 cycloalkylene group, wherein the C3-C6 cycloalkylene group 10 may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted 15 with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted 20 with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 4- to 7-membered saturated monocyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; 25 or R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; 30 or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- 35 membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; - 64 - or any two RL2and R21may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or 5 one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or any RL2, R21and R22may, together with the atoms to which they are 10 attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the three ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the 15 nitrogen atom of -NR21R22are all carbon atoms that are not substituted with an oxo (=O) group. In a further particular embodiment, -CONR2R3has the formula: 20 wherein: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the 25 -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 30 R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 35 and - 65 - each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group 5 may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted 10 with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 15 or R21and R22may together with the nitrogen atom to which they are attached form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3, R21and any RL2may, together with the atoms to which they are 20 attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; 25 provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. In one aspect of such an embodiment: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may 30 optionally be substituted with one or more fluoro groups and / or one or two groups RL2; R22is not selected from a -CO-R220, -SO-R220or -SO2-R220group; and each RL2is independently selected from a methyl or fluoromethyl group; or R3and any RL2may, together with the atoms to which they are attached, 35 form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; - 66 - or any RL2and R21may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 5 or R21and R22may together with the nitrogen atom to which they are attached form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3. 10 In one aspect, where -CONR2R3has the formula -CO-N(R3)-L2-NR21R22, R21is not hydrogen and R22is not hydrogen. In certain embodiments: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may 15 optionally be substituted with one or more fluoro groups and / or one or two groups RL2; each RL2is independently selected from a methyl or a fluoromethyl group; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 20 R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; or R21and R22may, together with the nitrogen atom to which they are 25 attached, form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon 30 atoms. Typically in such embodiments, R3is hydrogen. For example, -CONR2R3may have the formula: 35 - 67 - In one aspect of such embodiments: L2is a C2-C4 straight-chained alkylene group; 5 R3is hydrogen; R21is hydrogen or a methyl group; and R22is hydrogen or a C1-C3 alkyl or cyclopropyl group. In other embodiments: 10 L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group is substituted with one group RL2, and wherein the alkylene group may optionally be further substituted with one or more fluoro groups; R3and RL2, together with the atoms to which they are attached, form a 5- to 7- membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered 15 saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; or R3, R21and RL2may, together with the atoms to which they are attached, 20 form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and 25 each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. For example, -CONR2R3may have the formula: 30 . Typically in such embodiments: - 68 - R3and RL2, together with the atoms to which they are attached, form a 5- to 7- membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and 5 R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. Typically in such embodiments, R22is hydrogen or a methyl group. Most typically, R22is hydrogen. 10 In additional embodiments: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group is substituted with two groups RL2, and wherein the alkylene group may optionally be further substituted with one or more fluoro groups; 15 the two RL2, together with the carbon atom or carbon atoms to which they are attached, form a C3-C6 cycloalkylene group, wherein the C3-C6 cycloalkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 20 fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 25 R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 30 Typically in such additional embodiments, R3is hydrogen. Typically in such additional embodiments: R21is hydrogen or a methyl group; 35 R22is hydrogen or a -CO-R220, C1-C3 alkyl or cyclopropyl group; and R220is a C1-C3 alkyl or cyclopropyl group. For example, -CONR2R3may have the formula: - 69 - . In further embodiments: 5 L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the 10 -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 15 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or 20 more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 25 For example, -CONR2R3may have the formula: - 70 - 5 Typically in such further embodiments: L2is a C2-C4straight-chained alkylene group, wherein the alkylene group is substituted with one group RL2, and wherein the alkylene group may optionally be further substituted with one or more fluoro groups; and 10 R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group is 15 substituted with one group RL2; and R22is hydrogen or a methyl group. Typically in such further embodiments, R3is hydrogen. 20 In a separate embodiment, where Q2is O, -CONR2R3has the formula: wherein: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, 25 -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the - 71 - -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon 5 atom of the alkylene or the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group that is directly attached to the oxygen atom of -OR21is not substituted with an oxo (=O) group; R3is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated 10 hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of 15 any saturated hydrocarbyl group of R3that is directly attached to the nitrogen atom of N-R3is a carbon atom; R21is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted 20 with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R21that is directly attached to the oxygen atom of -OR21is a carbon atom that is not substituted with an oxo (=O) group; and 25 each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) 30 group and / or one, two, three or four groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three 35 or four groups RL3; or R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic group, wherein the 6- or 7- membered saturated monocyclic heterocyclic group may optionally be substituted with - 72 - one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 6- or 7-membered saturated monocyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group; 5 or any RL2and R21may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 4- to 7-membered 10 saturated monocyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group; or R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be 15 substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be 20 substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group; 25 or any two RL2and R21may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- 30 membered saturated bicyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-OR21contains no more than 12 carbon 35 atoms. As will be understood, in such an embodiment the compound is a compound of Formula (V): - 73 - Formula (V) wherein R1, X1-X4, A1-A6, Q1, R3, L2and R21are as defined in accordance with Formula (I). 5 Typically in such an embodiment: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon atom of the 10 alkylene group that is directly attached to the oxygen atom of -OR21is not substituted with an oxo (=O) group; each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the carbon atom or carbon atoms to which they are attached, form a C3-C6 cycloalkylene group, wherein the C3-C6 cycloalkylene group 15 may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted 20 with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted 25 with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 4- to 7-membered saturated monocyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group; or R3and any two RL2may, together with the atoms to which they are 30 attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be - 74 - substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein 5 the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo 10 (=O) group; or any two RL2and R21may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or15 one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group. 20 In a further particular embodiment, -CONR2R3has the formula: wherein: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, 25 -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; 30 R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL2is independently selected from a methyl or fluoromethyl group, or any35 two RL2may, together with the atom or atoms to which they are attached, form a C3- - 75 - C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 5 or R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, 10 form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, 15 wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-OR21contains no more than 10 carbon 20 atoms. In one aspect of such an embodiment: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups 25 RL2; and each RL2is independently selected from a methyl or fluoromethyl group; or R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted 30 with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and 35 each RL3is independently selected from a methyl or a fluoromethyl group. In one aspect, where -CONR2R3has the formula -CO-N(R3)-L2-OR21, R21is not hydrogen. - 76 - In certain embodiments: L2is a C2-C5 or a C2-C4 straight-chained alkylene group, wherein the alkylene group is substituted with one group RL2, and wherein the alkylene group may 5 optionally be further substituted with one or more fluoro groups; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered 10 saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-OR21contains no more than 10 carbon atoms. 15 Typically in such embodiments, R3is hydrogen. For example, -CONR2R3may have the formula: 20 In a separate embodiment, where Q2is S, -CONR2R3has the formula: wherein: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, 25 -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or a single 30 oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon atom of the alkylene or the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or - 77 - the -CH2CH2-NH-CH2CH2CH2- group that is directly attached to the sulphur atom of -SR21is not substituted with an oxo (=O) group; R3is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single 5 cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R3that is directly attached to the nitrogen atom of 10 N-R3is a carbon atom; R21is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the 15 saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R21that is directly attached to the sulphur atom of -SR21is a carbon atom that is not substituted with an oxo (=O) group; and each RL2is independently selected from a methyl or fluoromethyl group, or any20 two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; 25 or R3and any RL2may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; 30 or R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic group, wherein the 6- or 7- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 6- or 7-membered saturated 35 monocyclic heterocyclic group that are directly attached to the sulphur atom of -SR21are both carbon atoms that are not substituted with an oxo (=O) group; or any RL2and R21may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to - 78 - 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 4- to 7-membered saturated monocyclic heterocyclic group that are directly attached to the sulphur atom 5 of -SR21are both carbon atoms that are not substituted with an oxo (=O) group; or R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or 10 one, two, three or four groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or15 one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the sulphur atom of -SR21are both carbon atoms that are not substituted with an oxo (=O) group; or any two RL2and R21may, together with the atoms to which they are 20 attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the 25 sulphur atom of -SR21are both carbon atoms that are not substituted with an oxo (=O) group; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-SR21contains no more than 12 carbon atoms. 30 As will be understood, in such an embodiment the compound is a compound of Formula (VI): - 79 - Formula (VI) wherein R1, X1-X4, A1-A6, Q1, R3, L2and R21are as defined in accordance with Formula (I). 5 In a further particular embodiment, -CONR2R3has the formula: wherein: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, 10 -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or one or two 15 groups RL2; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and 20 each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two 25 groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to - 80 - 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 5 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may 10 optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-SR21contains no more than 10 carbon atoms. 15 In certain embodiments: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; 20 each RL2is independently selected from a methyl or a fluoromethyl group; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 25 provided that the group -CO-N(R3)-L2-SR21contains no more than 10 carbon atoms. Typically in such embodiments, R3is hydrogen. 30 For example, -CONR2R3may have the formula: . In certain embodiments, the compound is a compound of Formula (IIa): - 81 - Formula (IIa) wherein X1-X4, A1-A6, Q1, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 5 In other embodiments, the compound is a compound of Formula (IIb): Formula (IIb) wherein X1-X4, A1-A6, Q1, R13, r, s and t are as defined in accordance with Formula (I). 10 In certain other embodiments, the compound is a compound of Formula (IId): Formula (IId) wherein X1-X4, A1-A6, Q1, R12, R13, m, n, p, q, r and s are as defined in accordance with 15 Formula (I). In further embodiments, the compound is a compound of Formula (IIe): - 82 - Formula (IIe) wherein X1-X4, A1-A6, Q1, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 5 In yet further embodiments, the compound is a compound of Formula (IIf): wherein X1-X4, A1-A6, Q1, R12, R13, m, n, p, q, r and s are as defined in accordance with 10 Formula (I). In certain embodiments, the compound is a compound of Formula (IIIa): Formula (IIIa) 15 wherein X1-X4, A1-A6, Q1, Q2, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). - 83 - In other embodiments, the compound is a compound of Formula (IIIb): Formula (IIIb) 5 wherein X1-X4, A1-A6, Q1, Q2, L2, R21, R3, R13, r, s and t are as defined in accordance with Formula (I). In certain other embodiments, the compound is a compound of Formula (IIId): 10 Formula (IIId) wherein X1-X4, A1-A6, Q1, Q2, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In further embodiments, the compound is a compound of Formula (IIIe): 15 Formula (IIIe) - 84 - wherein X1-X4, A1-A6, Q1, Q2, L2, R21, R3, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In yet further embodiments, the compound is a compound of Formula (IIIf): 5 Formula (IIIf) wherein X1-X4, A1-A6, Q1, Q2, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 10 In certain embodiments, the compound is a compound of Formula (IVa): Formula (IVa) wherein X1-X4, A1-A6, Q1, L2, R21, R22, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 15 In other embodiments, the compound is a compound of Formula (IVb): - 85 - Formula (IVb) wherein X1-X4, A1-A6, Q1, L2, R21, R22, R3, R13, r, s and t are as defined in accordance with Formula (I). 5 In certain other embodiments, the compound is a compound of Formula (IVd): Formula (IVd) wherein X1-X4, A1-A6, Q1, L2, R21, R22, R3, R12, R13, m, n, p, q, r and s are as defined in 10 accordance with Formula (I). In further embodiments, the compound is a compound of Formula (IVe): Formula (IVe) 15 wherein X1-X4, A1-A6, Q1, L2, R21, R22, R3, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). - 86 - In yet further embodiments, the compound is a compound of Formula (IVf): Formula (IVf) wherein X1-X4, A1-A6, Q1, L2, R21, R22, R3, R12, R13, m, n, p, q, r and s are as defined in 5 accordance with Formula (I). In certain embodiments, the compound is a compound of Formula (Va): Formula (Va) 10 wherein X1-X4, A1-A6, Q1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In other embodiments, the compound is a compound of Formula (Vb): 15 Formula (Vb) - 87 - wherein X1-X4, A1-A6, Q1, L2, R21, R3, R13, r, s and t are as defined in accordance with Formula (I). In certain other embodiments, the compound is a compound of Formula (Vd): 5 Formula (Vd) wherein X1-X4, A1-A6, Q1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 10 In further embodiments, the compound is a compound of Formula (Ve): Formula (Ve) wherein X1-X4, A1-A6, Q1, L2, R21, R3, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 15 In yet further embodiments, the compound is a compound of Formula (Vf): - 88 - Formula (Vf) wherein X1-X4, A1-A6, Q1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 5 In certain embodiments, the compound is a compound of Formula (VIa): Formula (VIa) wherein X1-X4, A1-A6, Q1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in 10 accordance with Formula (I). In other embodiments, the compound is a compound of Formula (VIb): Formula (VIb) 15 wherein X1-X4, A1-A6, Q1, L2, R21, R3, R13, r, s and t are as defined in accordance with Formula (I). - 89 - In certain other embodiments, the compound is a compound of Formula (VId): Formula (VId) 5 wherein X1-X4, A1-A6, Q1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In further embodiments, the compound is a compound of Formula (VIe): 10 Formula (VIe) wherein X1-X4, A1-A6, Q1, L2, R21, R3, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In yet further embodiments, the compound is a compound of Formula (VIf): 15 Formula (VIf) - 90 - wherein X1-X4, A1-A6, Q1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). As stated in accordance with the first aspect of the invention: 5 X1is N, C-H, C-Hal or C-RX1; X2is N, C-H, C-Hal or C-RX2; X3is N, C-H, C-Hal or C-RX3; and X4is N or C; provided that no more than three of X1, X2, X3and X4are N; and 10 RX1, RX2and RX3are each independently selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may 15 optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. 20 Typically, when X4is N, A6is C. Typically, X4is C. Typically, when X4is C, A6is N. Typically, no more than two of X1, X2, X3and X4are N. 25 Typically, at least one of X1, X2, X3and X4is N. In a particular embodiment, at least one of X2and X3is N. More particularly, X2is N. Without wishing to be bound by theory, it is thought that the compounds of the 30 invention where at least one of X2and X3is N, and most particularly where X2is N, offer particular electronic properties that are advantageous to the pharmacological profile of the molecule. In one embodiment: 35 X1is N, C-H, C-Hal or C-RX1; X2is N, C-H, C-Hal or C-RX2; X3is C-H, C-Hal or C-RX3; and X4is N or C; - 91 - provided that at least one of X1, X2and X4is N, and that no more than two of X1, X2and X4are N. Typically, at least X1is N. In one aspect of such an embodiment: 5 X1is N, C-H, C-Hal or C-RX1; X2is N; X3is C-H, C-Hal or C-RX3; and X4is N or C; provided that no more than two of X1, X2and X4are N. Typically, X4is C. 10 In another embodiment: X1is N, C-H, C-Hal or C-RX1; X2is N, C-H, C-Hal or C-RX2; X3is N, C-H, C-Hal or C-RX3; and 15 X4is C; provided that no more than two of X1, X2and X3are N. Typically in such an embodiment, at least one of X1, X2and X3is N. Typically in such an embodiment, at least one of X2and X3is N. Typically, X2is N and 20 X3is C-H, C-Hal or C-RX3, or X3is N and X2is C-H, C-Hal or C-RX2. Most typically, X2is N. Typically in such an embodiment, X1is N and at least one of X2and X3is N. 25 In a further embodiment: X1is N, C-H, C-Hal or C-RX1; X2is N, C-H, C-Hal or C-RX2; X3is C-H, C-Hal or C-RX3; and X4is C; 30 provided that at least one of X1and X2is N. Typically, at least X1is N. In one aspect of such an embodiment: X1is N, C-H, C-Hal or C-RX1; X2is N; 35 X3is C-H, C-Hal or C-RX3; and X4is C. More typically in such an embodiment, X1is N and X2is N. - 92 - In one embodiment of the first aspect of the invention, RX1, RX2and RX3are each independently selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be 5 straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More typically, RX1, RX2and RX3are each independently selected from a C1-C4 saturated hydrocarbyl group, wherein the 10 hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton. More typically still, RX1, RX2and RX3are each independently selected from a methyl, 15 fluoromethyl, methoxy or fluoromethoxy group. Yet more typically, RX1, RX2and RX3are each independently selected from a methyl or fluoromethyl group. In a further embodiment: X1is N, C-H or C-Hal; 20 X2is N, C-H or C-Hal; X3is N, C-H or C-Hal; and X4is N or C; provided that no more than three of X1, X2, X3and X4are N. Typically in such an embodiment, no more than two of X1, X2, X3and X4are N. In a particular 25 embodiment, at least one of X2and X3is N. More particularly, X2is N. Typically, at least one of X1, X2, X3and X4is N. Typically, at least X1is N. In one aspect of such an embodiment: X1is N, C-H or C-Hal; 30 X2is N; X3is N, C-H or C-Hal; and X4is N or C; provided that no more than three of X1, X2, X3and X4are N. Typically in such an embodiment, no more than two of X1, X2, X3and X4are N. Typically, X4is C. 35 In another aspect of such an embodiment: X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; - 93 - X3is N, C-H or C-Hal; and X4is C; provided that no more than two of X1, X2and X3are N. Typically in such an embodiment, at least one of X1, X2and X3is N. 5 Typically in such an embodiment, at least one of X2and X3is N. Typically, X2is N and X3is C-H or C-Hal, or X3is N and X2is C-H or C-Hal. Most typically, X2is N. Typically in such an embodiment, X1is N and at least one of X2and X3is N. 10 In one embodiment: X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; X3is C-H or C-Hal; and 15 X4is N or C; provided that at least one of X1, X2and X4is N, and that no more than two of X1, X2and X4are N. Typically, at least X1is N. In one aspect of such an embodiment: 20 X1is N, C-H or C-Hal; X2is N; X3is C-H or C-Hal; and X4is N or C; provided that no more than two of X1, X2and X4are N. 25 In a further embodiment: X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; X3is C-H or C-Hal; and 30 X4is C; provided that at least one of X1and X2is N. Typically, at least X1is N. In one aspect of such an embodiment: X1is N, C-H or C-Hal; 35 X2is N; X3is C-H or C-Hal; and X4is C. - 94 - More typically in such an embodiment, X1is N and X2is N. More typically still, X1is N, X2is N and X3is C-H. In a further embodiment: 5 X1is N or C-H; X2is N or C-H; X3is N or C-H; and X4is C; provided that no more than two of X1, X2and X3are N. Typically in such an 10 embodiment, at least one of X1, X2and X3is N. Typically in such an embodiment, at least one of X2and X3is N. Typically, X2is N and X3is C-H, or X3is N and X2is C-H. Most typically, X2is N. 15 Typically in such an embodiment, X1is N and at least one of X2and X3is N. Most typically, X1is N, X2is N and X3is C-H. As stated in accordance with the first aspect of the invention: Q1is O, S, N, N-H, N-RQ1, C-H, C-Hal, or C-RQ2; 20 RQ1is selected from a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O 25 and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of RQ1that is directly attached to the nitrogen atom of N-RQ1is a carbon atom; and 30 RQ2is selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more 35 heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. - 95 - In one embodiment of the first aspect of the invention, RQ1and RQ2are each independently selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-RQ3group, 5 wherein RQ3is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically, RQ1and RQ2are each independently selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group. More typically still, RQ1and RQ2are each independently selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 10 fluorocyclopropyl group. Yet more typically, RQ1and RQ2are each independently selected from a methyl or fluoromethyl group. Typically, Q1is O, S, N-H, N-RQ1, C-H, C-Hal, or C-RQ2. More typically, Q1is O, S, N-H or N-RQ1. For example, Q1may be O, S, N-H or N-RQ1, wherein RQ1is selected from a 15 C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-RQ3group, wherein RQ3is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group. More typically still, Q1is S, N-H or N-RQ1. Typically in such an embodiment, RQ1is a methyl or fluoromethyl group. Yet more typically, Q1is S or N-H. 20 In one embodiment, Q1is S. In another embodiment, Q1is O. 25 In yet another embodiment, Q1is N-H or N-RQ1, wherein RQ1is a methyl or fluoromethyl group. Typically in such an embodiment, Q1is N-H. As stated in accordance with the first aspect of the invention: A1is N, C-H, C-Hal or C-RA1; 30 A2is N, C-H, C-Hal or C-RA2; A3is N, C-H, C-Hal or C-RA3; A4is N, C-H, C-Hal or C-RA4; and A5is N or C; provided that no more than three of A1, A2, A3, A4and A5are N; and 35 RA1, RA2, RA3and RA4are each independently selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted - 96 - with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected 5 from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. Typically, no more than two of A1, A2, A3, A4and A5are N. More typically, no more than one of A1, A2, A3, A4and A5is N. 10 Typically, when A5is N, X4is N, A6is C and Q1is N, C-H, C-Hal, or C-RQ2. More typically, when A5is N, X4is N, A6is C and Q1is C-H, C-Hal, or C-RQ2. Typically, where Q1is O, S, N-H or N-RQ1, A5is C. 15 In one embodiment, A1is N, C-H, C-Hal or C-RA1; A2is N, C-H, C-Hal or C-RA2; A3is N, C-H, C-Hal or C-RA3; A4is N, C-H, C-Hal or C-RA4; and 20 A5is C; provided that no more than two of A1, A2, A3and A4are N. Typically in such an embodiment, no more than one of A1, A2, A3and A4is N. Typically, where one of A1, A2, A3and A4is N, A2is N or A3is N. More typically, A3is N. 25 In a further embodiment, A1is C-H C-Hal or C-RA1; A2is C-H, C-Hal or C-RA2; A3is C-H, C-Hal or C-RA3; 30 A4is C-H, C-Hal or C-RA4; and A5is C. Typically in the above embodiments, no more than two of A1, A2, A3and A4are C-RA1, C-RA2, C-RA3or C-RA4. More typically, no more than one of A1, A2, A3and A4is C-RA1, 35 C-RA2, C-RA3or C-RA4. In one embodiment, RA1, RA2, RA3and RA4are each independently selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2 or a C1-C4 saturated or unsaturated hydrocarbyl - 97 - group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its 5 carbon skeleton. More typically, RA1, RA2, RA3and RA4are each independently selected from a C1-C4 saturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the hydrocarbyl group may optionally include a single 10 heteroatom selected from N and O in its carbon skeleton. More typically still, RA1, RA2, RA3and RA4are each independently selected from a methyl, fluoromethyl, methoxy or fluoromethoxy group. Yet more typically, RA1, RA2, RA3and RA4are each independently selected from a methyl or fluoromethyl group. 15 In another embodiment, A1is N, C-H or C-Hal; A2is N, C-H or C-Hal; A3is N, C-H or C-Hal; A4is N, C-H or C-Hal; and 20 A5is C; provided that no more than two of A1, A2, A3and A4are N. Typically in such an embodiment, no more than one of A1, A2, A3and A4is N. Typically, where one of A1, A2, A3and A4is N, A2is N or A3is N. More typically, A3is N. 25 In a further embodiment, A1is C-H or C-Hal; A2is C-H or C-Hal; A3is C-H or C-Hal; 30 A4is C-H or C-Hal; and A5is C. Most typically, A1is C-H, A2is C-H, A3is C-H, A4is C-H and A5is C. 35 As stated in accordance with the first aspect of the invention, A6is N or C. Typically, A6is N. - 98 - As stated in accordance with the first aspect of the invention, each Hal is independently selected from a fluoro, chloro, bromo or iodo group. Typically, each Hal is independently selected from a fluoro, chloro or bromo group. 5 In one embodiment of the first aspect of the invention, the compound is a compound of Formula (VII): Formula (VII) wherein Q1is O, S, N-H or N-RQ1, and R1, R2, R3, X1-X3, A1-A4and RQ1are as defined in 10 accordance with Formula (I). In another embodiment of the first aspect of the invention, the compound is a compound of Formula (VIIa): 15 Formula (VIIa) wherein Q1is O, S, N-H or N-RQ1, and R2, R3, X1-X3, A1-A4, RQ1, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a further embodiment of the first aspect of the invention, the compound is a 20 compound of Formula (VIIb): - 99 - Formula (VIIb) wherein Q1is O, S, N-H or N-RQ1, and R2, R3, X1-X3, A1-A4, RQ1, R13, r, s and t are as defined in accordance with Formula (I). 5 In an additional embodiment of the first aspect of the invention, the compound is a compound of Formula (VIId): Formula (VIId) 10 wherein Q1is O, S, N-H or N-RQ1, and R2, R3, X1-X3, A1-A4, RQ1, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In another embodiment of the first aspect of the invention, the compound is a compound of Formula (VIIe): 15 Formula (VIIe) - 100 - wherein Q1is O, S, N-H or N-RQ1, and R2, R3, X1-X3, A1-A4, RQ1, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In yet another embodiment of the first aspect of the invention, the compound is a 5 compound of Formula (VIIf): wherein and s are as defined in accordance with Formula (I). 10 In one embodiment of the first aspect of the invention, the compound is a compound of Formula (VIII): 15 Formula (VIII) wherein Q1is O, S, N-H or N-RQ1, and R1, X1-X3, A1-A4and RQ1are as defined in accordance with Formula (I). In another embodiment of the first aspect of the invention, the compound is a 20 compound of Formula (VIIIa): - 101 - Formula (VIIIa) wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 5 In a further embodiment of the first aspect of the invention, the compound is a compound of Formula (VIIIb): Formula (VIIIb) 10 wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, R13, r, s and t are as defined in accordance with Formula (I). In an additional embodiment of the first aspect of the invention, the compound is a compound of Formula (VIIId): 15 Formula (VIIId) - 102 - wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In another embodiment of the first aspect of the invention, the compound is a 5 compound of Formula (VIIIe): Formula (VIIIe) wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 10 In yet another embodiment of the first aspect of the invention, the compound is a compound of Formula (VIIIf): Formula (VIIIf) 15 wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In one embodiment of the first aspect of the invention, the compound is a compound of Formula (IX): - 103 - Formula (IX) wherein Q1is O, S, N-H or N-RQ1, and R1, X1-X3, A1-A4, RQ1, Q2, L2, R21and R3are as defined in accordance with Formula (I). 5 In another embodiment of the first aspect of the invention, the compound is a compound of Formula (IXa): Formula (IXa) 10 wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, Q2, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a further embodiment of the first aspect of the invention, the compound is a compound of Formula (IXb): 15 Formula (IXb) - 104 - wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, Q2, L2, R21, R3, R13, r, s and t are as defined in accordance with Formula (I). In an additional embodiment of the first aspect of the invention, the compound is a 5 compound of Formula (IXd): Formula (IXd) wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, Q2, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 10 In another embodiment of the first aspect of the invention, the compound is a compound of Formula (IXe): Formula (IXe) 15 wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, Q2, L2, R21, R3, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In yet another embodiment of the first aspect of the invention, the compound is a compound of Formula (IXf): - 105 - wherein p, q, r and s are as defined in accordance with Formula (I). 5 In one embodiment of the first aspect of the invention, the compound is a compound of Formula (X): Formula (X) 10 wherein Q1is O, S, N-H or N-RQ1, and R1, X1-X3, A1-A4, RQ1, L2, R21, R22and R3are as defined in accordance with Formula (I). In another embodiment of the first aspect of the invention, the compound is a compound of Formula (Xa): 15 Formula (Xa) - 106 - wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, L2, R21, R22, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a further embodiment of the first aspect of the invention, the compound is a 5 compound of Formula (Xb): wherein r, s and t are as defined in accordance with Formula (I). 10 In an additional embodiment of the first aspect of the invention, the compound is a compound of Formula (Xd): Formula (Xd) 15 wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, L2, R21, R22, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In another embodiment of the first aspect of the invention, the compound is a compound of Formula (Xe): - 107 - Formula (Xe) wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, L2, R21, R22, R3, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 5 In yet another embodiment of the first aspect of the invention, the compound is a compound of Formula (Xf): 10 wherein p, q, r and s are as defined in accordance with Formula (I). In one embodiment of the first aspect of the invention, the compound is a compound of Formula (XI): 15 Formula (XI) - 108 - wherein Q1is O, S, N-H or N-RQ1, and R1, X1-X3, A1-A4, RQ1, L2, R21and R3are as defined in accordance with Formula (I). In another embodiment of the first aspect of the invention, the compound is a 5 compound of Formula (XIa): Formula (XIa) wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 10 In a further embodiment of the first aspect of the invention, the compound is a compound of Formula (XIb): 15 wherein and t are as defined in accordance with Formula (I). In an additional embodiment of the first aspect of the invention, the compound is a compound of Formula (XId): - 109 - Formula (XId) wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 5 In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIe): Formula (XIe) 10 wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, L2, R21, R3, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In yet another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIf): 15 Formula (XIf) - 110 - wherein Q1is O, S, N-H or N-RQ1, and X1-X3, A1-A4, RQ1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In one embodiment of the first aspect of the invention, the compound is a compound 5 of Formula (XII): Formula (XII) wherein Q1is O, S, N-H or N-RQ1, and R1, R2, R3, X1, X2and RQ1are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N 10 and X2is N. In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIIa): 15 wherein and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 20 In a further embodiment of the first aspect of the invention, the compound is a compound of Formula (XIIb): - 111 - Formula (XIIb) wherein Q1is O, S, N-H or N-RQ1, and R2, R3, X1, X2, RQ1, R13, r, s and t are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N 5 and X2is N. In an additional embodiment of the first aspect of the invention, the compound is a compound of Formula (XIId): 10 wherein and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 15 In another embodiment of the first aspect of the invention,the compound is a compound of Formula (XIIe): - 112 - Formula (XIIe) wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, R2, R3, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an 5 embodiment, X1is N and X2is N. In yet another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIIf): 10 Formula (XIIf) wherein Q1is O, S, N-H or N-RQ1, and R2, R3, X1, X2, RQ1, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 15 In one embodiment of the first aspect of the invention, the compound is a compound of Formula (XIII): - 113 - Formula (XIII) wherein Q1is O, S, N-H or N-RQ1, and R1, X1, X2and RQ1are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 5 In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIIIa): Formula (XIIIa) 10 wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. In a further embodiment of the first aspect of the invention, the compound is a 15 compound of Formula (XIIIb): Formula (XIIIb) - 114 - wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, R13, r, s and t are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 5 In an additional embodiment of the first aspect of the invention, the compound is a compound of Formula (XIIId): wherein are as 10 defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIIIe): 15 wherein are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 20 In yet another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIIIf): - 115 - Formula (XIIIf) wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, 5 X1is N and X2is N. In one embodiment of the first aspect of the invention, the compound is a compound of Formula (XIV): 10 Formula (XIV) wherein Q1is O, S, N-H or N-RQ1, and R1, L2, Q2, R21, R3, X1, X2and RQ1are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 15 In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIVa): - 116 - wherein and s are as defined in accordance with Formula (I). In a particular aspect of such an 5 embodiment, X1is N and X2is N. In a further embodiment of the first aspect of the invention, the compound is a compound of Formula (XIVb): 10 wherein t are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 15 In an additional embodiment of the first aspect of the invention, the compound is a compound of Formula (XIVd): Formula (XIVd) - 117 - wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, L2, Q2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 5 In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIVe): Formula (XIVe) wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, L2, Q2, R21, R3, X12, R13, m, n, p, q, r 10 and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. In yet another embodiment of the first aspect of the invention, the compound is a compound of Formula (XIVf): 15 Formula (XIVf) wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, Q2, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 20 In one embodiment of the first aspect of the invention, the compound is a compound of Formula (XV): - 118 - Formula (XV) wherein Q1is O, S, N-H or N-RQ1, and R1, L2, R21, R22, R3, X1, X2and RQ1are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N 5 and X2is N. In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XVa): 10 wherein and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 15 In a further embodiment of the first aspect of the invention, the compound is a compound of Formula (XVb): Formula (XVb) - 119 - wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, L2, R21, R22, R3, R13, r, s and t are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 5 In an additional embodiment of the first aspect of the invention, the compound is a compound of Formula (XVd): Formula (XVd) wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, L2, R21, R22, R3, R12, R13, m, n, p, q, r 10 and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XVe): 15 Formula (XVe) wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, L2, R21, R22, R3, X12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 20 In yet another embodiment of the first aspect of the invention, the compound is a compound of Formula (XVf): - 120 - Formula (XVf) wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, L2, R21, R22, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an 5 embodiment, X1is N and X2is N. In one embodiment of the first aspect of the invention, the compound is a compound of Formula (XVI): 10 Formula (XVI) wherein Q1is O, S, N-H or N-RQ1, and R1, L2, R21, R3, X1, X2and RQ1are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 15 In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XVIa): - 121 - wherein p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an 5 embodiment, X1is N and X2is N. In a further embodiment of the first aspect of the invention, the compound is a compound of Formula (XVIb): 10 wherein are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 15 In an additional embodiment of the first aspect of the invention, the compound is a compound of Formula (XVId): Formula (XVId) - 122 - wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. 5 In another embodiment of the first aspect of the invention, the compound is a compound of Formula (XVIe): Formula (XVIe) wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, L2, R21, R3, X12, R13, m, n, p, q, r and 10 s are as defined in accordance with Formula (I). In a particular aspect of such an embodiment, X1is N and X2is N. In yet another embodiment of the first aspect of the invention, the compound is a compound of Formula (XVIf): 15 Formula (XVIf) wherein Q1is O, S, N-H or N-RQ1, and X1, X2, RQ1, L2, R21, R3, R12, R13, m, n, p, q, r and s are as defined in accordance with Formula (I). 20 As will be understood, insofar as practical, embodiments directed to one substituent or moiety (such as a given R or X group) may be read in conjunction with embodiments directed to a different substituent or moiety. - 123 - For example, in a first exemplary embodiment, there is provided a compound of Formula (VII) as defined above, wherein: R1is a saturated heterocyclic bicyclic group, wherein the saturated heterocyclic bicyclic group may optionally be substituted with one or more fluoro groups and / or 5 one or two oxo (=O) groups, and / or one or two groups R11; each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single 10 oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; R2and R3are each independently selected from hydrogen or a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained 15 or branched, or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or oxo (=O) groups, wherein the saturated hydrocarbyl group may optionally include one, two, three or four heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may 20 optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; or R2and R3together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated monocyclic group or a 6- to 10-membered saturated bicyclic group, wherein the monocyclic or the bicyclic group may optionally be 25 substituted with one or more substituents each independently selected from a fluoro, oxo (=O), -OH, -NH2 or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or oxo (=O) groups, and wherein the saturated 30 hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; X1is N, C-H, C-Hal or C-RX1; X2is N, C-H, C-Hal or C-RX2; and X3is N, C-H, C-Hal or C-RX3; 35 provided that no more than two of X1, X2and X3are N; RX1, RX2and RX3are each independently selected from a methyl, fluoromethyl, methoxy or fluoromethoxy group; Q1is O, S, N-H or N-RQ1; - 124 - RQ1is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-RQ3group; RQ3is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 5 A1is N, C-H, C-Hal or C-RA1; A2is N, C-H, C-Hal or C-RA2; A3is N, C-H, C-Hal or C-RA3; and A4is N, C-H, C-Hal or C-RA4; provided that no more than two of A1, A2, A3and A4are N, and that no more 10 than two of A1, A2, A3and A4are C-RA1, C-RA2, C-RA3or C-RA4; RA1, RA2, RA3and RA4are each independently selected from a methyl, fluoromethyl, methoxy or fluoromethoxy group; and each Hal is independently selected from a fluoro, chloro or bromo group. 15 Typically in accordance with the first exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. In one aspect of the first exemplary embodiment, R1is a saturated fused bicyclic heterocyclic group, wherein the saturated fused bicyclic heterocyclic group comprises 20 at least one ring nitrogen atom, wherein the saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11. Typically in such an aspect, at least one of X2and X3is N. Most typically, X2is N. 25 In another aspect of the first exemplary embodiment, R1is a saturated spiro bicyclic heterocyclic group, wherein the saturated spiro bicyclic heterocyclic group comprises at least one ring nitrogen atom, wherein the saturated spiro bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11. Typically in such an aspect, at least one of 30 X2and X3is N. Most typically, X2is N. In a further aspect of the first exemplary embodiment, R1is a saturated bridged bicyclic heterocyclic group, wherein the saturated bridged bicyclic heterocyclic group comprises at least one ring nitrogen atom, wherein the saturated bridged bicyclic 35 heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11. Typically in such an aspect, at least one of X2and X3is N. Most typically, X2is N. - 125 - In a second exemplary embodiment, there is provided a compound of Formula (VIIa) as defined above, wherein: R2is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; 5 and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; or R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group, any of which may optionally be 10 fluoro-substituted; X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; and X3is N, C-H or C-Hal; provided that no more than two of X1, X2and X3are N; 15 Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; A1is N, C-H or C-Hal; A2is N, C-H or C-Hal; A3is N, C-H or C-Hal; and 20 A4is N, C-H or C-Hal; provided that no more than one of A1, A2, A3and A4is N; each Hal is independently selected from a fluoro, chloro or bromo group; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; 25 p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: m + n = 2 or 3; p + q = 2 or 3; 30 when m = 0, q is 1, 2 or 3; when n = 0, p is 1, 2 or 3; when p = 0, n is 1, 2 or 3; and when q = 0, m is 1, 2 or 3; and wherein: 35 r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; - 126 - R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each R13is independently selected from a methyl or fluoromethyl group. 5 Typically in accordance with the second exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. Typically in accordance with the second exemplary embodiment: m is 1 or 2; 10 n is 1 or 2; p is 0, 1 or 2; and q is 1 or 2; provided that: m + n = 2 or 3; and 15 p + q = 2 or 3; r is 0; and s is 0. In one aspect of the second exemplary embodiment, the compound is a compound of 20 Formula (VIIIa) as defined above. Typically in such an aspect at least one of X2and X3is N. Most typically, X2is N. In another aspect of the second exemplary embodiment the compound is a compound of Formula (XIIa) as defined above. Typically in such an aspect: 25 R2is selected from hydrogen or a methyl or ethyl group; and R3is selected from hydrogen or a methyl or ethyl group; or R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl or piperidinyl group; X1is N; 30 X2is N or C-H; Q1is S or N-H; m is 1 or 2; n is 1 or 2; p is 0, 1 or 2; and 35 q is 1 or 2; provided that: m + n = 2 or 3; and p + q = 2 or 3; - 127 - r is 0; s is 0; and R12is hydrogen or a methyl or fluoromethyl group. 5 Typically in such an aspect, X2is N. In a further aspect of the second exemplary embodiment the compound is a compound of Formula (XIIIa) as defined above. Typically in such an aspect: X1is N; 10 X2is N or C-H; Q1is S or N-H; m is 1 or 2; n is 1 or 2; p is 0, 1 or 2; and 15 q is 1 or 2; provided that: m + n = 2 or 3; and p + q = 2 or 3; r is 0; 20 s is 0; and R12is hydrogen or a methyl or fluoromethyl group. Typically in such an aspect, X2is N. 25 In a third exemplary embodiment, there is provided a compound of Formula (VIIb) as defined above, wherein: R2is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; and 30 R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; or R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group, any of which may optionally be fluoro-substituted; 35 X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; and X3is N, C-H or C-Hal; provided that no more than two of X1, X2and X3are N; - 128 - Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; A1is N, C-H or C-Hal; A2is N, C-H or C-Hal; 5 A3is N, C-H or C-Hal; and A4is N, C-H or C-Hal; provided that no more than one of A1, A2, A3and A4is N; each Hal is independently selected from a fluoro, chloro or bromo group; r is 0, 1 or 2; 10 s is 0, 1 or 2; t is 1 or 2; and each R13is independently selected from a methyl or fluoromethyl group. Typically in accordance with the third exemplary embodiment, at least one of X2and 15 X3is N. Most typically, X2is N. Typically in accordance with the third exemplary embodiment, r is 0, s is 0, and t is 1. In one aspect of the third exemplary embodiment, the compound is a compound of 20 Formula (VIIIb) as defined above. Typically in such an aspect at least one of X2and X3is N. Most typically, X2is N. In another aspect of the third exemplary embodiment the compound is a compound of Formula (XIIb) as defined above. Typically in such an aspect: 25 R2is selected from hydrogen or a methyl or ethyl group; and R3is selected from hydrogen or a methyl or ethyl group; or R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl or piperidinyl group; X1is N; 30 X2is N or C-H; Q1is S or N-H; r is 0; s is 0; and t is 1 or 2. 35 Typically in such an aspect, X2is N. - 129 - In a further aspect of the third exemplary embodiment the compound is a compound of Formula (XIIIb) as defined above. Typically in such an aspect: X1is N; X2is N or C-H; 5 Q1is S or N-H; r is 0; s is 0; and t is 1. 10 Typically in such an aspect, X2is N. In a fourth exemplary embodiment, there is provided a compound of Formula (VIIe) as defined above, wherein: R2is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 15 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; or R2and R3together with the nitrogen atom to which they are attached form a 20 azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group, any of which may optionally be fluoro-substituted; X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; and X3is N, C-H or C-Hal; 25 provided that no more than two of X1, X2and X3are N; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; A1is N, C-H or C-Hal; A2is N, C-H or C-Hal; 30 A3is N, C-H or C-Hal; and A4is N, C-H or C-Hal; provided that no more than one of A1, A2, A3and A4is N; each Hal is independently selected from a fluoro, chloro or bromo group; X12is O or NR12; 35 m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; and q is 0, 1, 2, 3 or 4; - 130 - provided that: m + n = 3 or 4; p + q = 3 or 4; when m = 0, q is 1, 2, 3 or 4 and p is 1, 2, 3 or 4; 5 when n = 0, q is 1, 2, 3 or 4 and p is 1, 2, 3 or 4; when p = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and when q = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and wherein: r is 0, 1 or 2; 10 s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and 15 each R13is independently selected from a methyl or fluoromethyl group. Typically in accordance with the fourth exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. 20 Typically in accordance with the fourth exemplary embodiment: m is 1 or 2; n is 1 or 2; p is 0, 1 or 2; and q is 2 or 3; 25 provided that: m + n = 3 or 4; and p + q = 3 or 4; r is 0; and s is 0. 30 In one aspect of the fourth exemplary embodiment, the compound is a compound of Formula (VIIIe) as defined above. Typically in such an aspect at least one of X2and X3is N. Most typically, X2is N. 35 In another aspect of the fourth exemplary embodiment the compound is a compound of Formula (XIIe) as defined above. Typically in such an aspect: R2is selected from hydrogen or a methyl or ethyl group; and R3is selected from hydrogen or a methyl or ethyl group; or - 131 - R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl or piperidinyl group; X1is N; X2is N or C-H; 5 Q1is S or N-H; m is 1 or 2; n is 1 or 2; p is 0, 1 or 2; and q is 2 or 3; 10 provided that: m + n = 3 or 4; and p + q = 3 or 4; r is 0; s is 0; and 15 R12is hydrogen or a methyl or fluoromethyl group. Typically in such an aspect, X2is N. In a further aspect of the fourth exemplary embodiment the compound is a compound 20 of Formula (XIIIe) as defined above. Typically in such an aspect: X1is N; X2is N or C-H; Q1is S or N-H; m is 2; 25 n is 1 or 2; p is 1 or 2; q is 2; r is 0; s is 0; and 30 R12is hydrogen or a methyl or fluoromethyl group. Typically in such an aspect, X2is N. In a fifth exemplary embodiment, there is provided a compound of Formula (VIIf) as 35 defined above, wherein: R2is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; and - 132 - R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; or R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group, any of which may optionally be 5 fluoro-substituted; X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; and X3is N, C-H or C-Hal; provided that no more than two of X1, X2and X3are N; 10 Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; A1is N, C-H or C-Hal; A2is N, C-H or C-Hal; A3is N, C-H or C-Hal; and 15 A4is N, C-H or C-Hal; provided that no more than one of A1, A2, A3and A4is N; each Hal is independently selected from a fluoro, chloro or bromo group; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; 20 p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: m + n = 3 or 4; p + q = 2 or 3; 25 when m = 0, p is 1, 2 or 3; when n = 0, p is 1, 2 or 3; and when p = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and wherein: r is 0, 1 or 2; 30 s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; and each R13is independently selected from a methyl or fluoromethyl group. 35 Typically in accordance with the fifth exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. Typically in accordance with the fifth exemplary embodiment: - 133 - m is 1 or 2; n is 1 or 2; p is 1 or 2; and q is 1 or 2; 5 provided that: m + n = 3 or 4; and p + q = 2 or 3; r is 0; and s is 0. 10 In one aspect of the fifth exemplary embodiment, the compound is a compound of Formula (VIIIf) as defined above. Typically in such an aspect at least one of X2and X3is N. Most typically, X2is N. 15 In another aspect of the fifth exemplary embodiment the compound is a compound of Formula (XIIf) as defined above. Typically in such an aspect: R2is selected from hydrogen or a methyl or ethyl group; and R3is selected from hydrogen or a methyl or ethyl group; or R2and R3together with the nitrogen atom to which they are attached form a 20 azetidinyl, pyrrolidinyl or piperidinyl group; X1is N; X2is N or C-H; Q1is S or N-H; m is 2; 25 n is 2; p is 1; q is 1; r is 0; s is 0; and 30 R12is hydrogen or a methyl or fluoromethyl group. Typically in such an aspect, X2is N. In a further aspect of the fifth exemplary embodiment the compound is a compound of 35 Formula (XIIIf) as defined above. Typically in such an aspect: X1is N; X2is N or C-H; Q1is S or N-H; - 134 - m is 2; n is 2; p is 1; q is 1; 5 r is 0; s is 0; and R12is hydrogen or a methyl or fluoromethyl group. Typically in such an aspect, X2is N. 10 In a sixth exemplary embodiment, there is provided a compound of Formula (IX) as defined above, wherein: R1is a saturated heterocyclic bicyclic group, wherein the saturated heterocyclic bicyclic group may optionally be substituted with one or more fluoro groups and / or 15 one or two oxo (=O) groups, and / or one or two groups R11; each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single 20 oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; X1is N, C-H, C-Hal or C-RX1; X2is N, C-H, C-Hal or C-RX2; and 25 X3is N, C-H, C-Hal or C-RX3; provided that no more than two of X1, X2and X3are N; RX1, RX2and RX3are each independently selected from a methyl, fluoromethyl, methoxy or fluoromethoxy group; Q1is O, S, N-H or N-RQ1; 30 RQ1is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-RQ3group; RQ3is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; A1is N, C-H, C-Hal or C-RA1; 35 A2is N, C-H, C-Hal or C-RA2; A3is N, C-H, C-Hal or C-RA3; and A4is N, C-H, C-Hal or C-RA4; - 135 - provided that no more than two of A1, A2, A3and A4are N, and that no more than two of A1, A2, A3and A4are C-RA1, C-RA2, C-RA3or C-RA4; RA1, RA2, RA3and RA4are each independently selected from a methyl, fluoromethyl, methoxy or fluoromethoxy group; 5 each Hal is independently selected from a fluoro, chloro or bromo group; Q2is O, S or NR22; L2is a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes a single heteroatom independently selected from O and N in its carbon skeleton, wherein L2has a chain length of from 2 to 6 atoms, and wherein 10 L2may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four groups RL2; R3is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted 15 with one or more fluoro groups and / or one or two oxo (=O) groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; R21is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single 20 cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; R22is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated 25 hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety 30 in the saturated hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; each RL2is independently selected from a methyl or fluoromethyl group; or R3and any RL2may, together with the atoms to which they are attached, 35 form a 3- to 7-membered saturated monocyclic heterocyclic group, wherein the 3- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four groups RL3; - 136 - or R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic group, wherein the 6- or 7- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three 5 or four groups RL3; or any two RL2may, together with the atom or atoms to which they are attached, form a 3- to 7-membered saturated monocyclic group, wherein the 3- to 7- membered saturated monocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four 10 groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 3- to 7-membered saturated monocyclic heterocyclic group, wherein the 3- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, 15 three or four groups RL3; or R21and R22may, together with the nitrogen atom to which they are attached form a 3- to 7-membered saturated monocyclic heterocyclic group, wherein the 3- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, 20 three or four groups RL3; or R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or 25 one, two, three or four groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or 30 one, two, three or four groups RL3; or R3, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10- membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three 35 or four groups RL3; or any two RL2and R21may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be - 137 - substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four groups RL3; or any RL2, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein 5 the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups and / or one, two, three or four groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-Q2-R21contains no more than 12 carbon 10 atoms. Typically in accordance with the sixth exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. 15 In one aspect of the sixth exemplary embodiment, R1is a saturated fused bicyclic heterocyclic group, wherein the saturated fused bicyclic heterocyclic group comprises at least one ring nitrogen atom, wherein the saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11. Typically in such an aspect, at least 20 one of X2and X3is N. Most typically, X2is N. In another aspect of the sixth exemplary embodiment, R1is a saturated spiro bicyclic heterocyclic group, wherein the saturated spiro bicyclic heterocyclic group comprises at least one ring nitrogen atom, wherein the saturated spiro bicyclic heterocyclic group 25 may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11. Typically in such an aspect, at least one of X2and X3is N. Most typically, X2is N. In a further aspect of the sixth exemplary embodiment, R1is a saturated bridged 30 bicyclic heterocyclic group, wherein the saturated bridged bicyclic heterocyclic group comprises at least one ring nitrogen atom, wherein the saturated bridged bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11. Typically in such an aspect, at least one of X2and X3is N. Most typically, X2is N. 35 In a seventh exemplary embodiment, there is provided a compound of Formula (Xa) as defined above, wherein: X1is N, C-H or C-Hal; - 138 - X2is N, C-H or C-Hal; and X3is N, C-H or C-Hal; provided that no more than two of X1, X2and X3are N; Q1is O, S, N-H or N-RQ1; 5 RQ1is selected from a methyl or fluoromethyl group; A1is N, C-H or C-Hal; A2is N, C-H or C-Hal; A3is N, C-H or C-Hal; and A4is N, C-H or C-Hal; 10 provided that no more than one of A1, A2, A3and A4is N; each Hal is independently selected from a fluoro, chloro or bromo group; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; and 15 q is 0, 1, 2 or 3; provided that: m + n = 2 or 3; p + q = 2 or 3; when m = 0, q is 1, 2 or 3; 20 when n = 0, p is 1, 2 or 3; when p = 0, n is 1, 2 or 3; and when q = 0, m is 1, 2 or 3; and wherein: r is 0, 1 or 2; 25 s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 30 each R13is independently selected from a methyl or fluoromethyl group; L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the 35 -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; - 139 - R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 5 R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL2is independently selected from a methyl or fluoromethyl group, or any10 two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 15 or R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, 20 form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R21and R22may together with the nitrogen atom to which they are attached form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 25 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may 30 optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 35 Typically in accordance with the seventh exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. - 140 - Typically in accordance with the seventh exemplary embodiment: m is 1 or 2; n is 1 or 2; p is 0, 1 or 2; and 5 q is 1 or 2; provided that: m + n = 2 or 3; and p + q = 2 or 3; r is 0; and 10 s is 0. In one aspect of the seventh exemplary embodiment: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups 15 RL2; each RL2is independently selected from a methyl or a fluoromethyl group; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 20 fluorocyclopropyl group; and R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; or R21and R22may, together with the nitrogen atom to which they are attached, form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein 25 the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 30 For example, the compound may be a compound of Formula (XVa) as defined above, wherein: X1is N or C-H; X2is N or C-H; 35 Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; m is 1 or 2; n is 1 or 2; - 141 - p is 0, 1 or 2; and q is 1 or 2; provided that: m + n = 2 or 3; and 5 p + q = 2 or 3; r is 0; s is 0; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; 10 R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; 15 each RL2is independently selected from a methyl or a fluoromethyl group; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and 20 R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; or R21and R22may, together with the nitrogen atom to which they are attached, form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be 25 substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 30 Typically in such an example, at least one of X1and X2is N. More typically, X1is N or C-H and X2is N. Most typically, X1is N and X2is N. In another aspect of the seventh exemplary embodiment: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group is 35 substituted with one group RL2, and wherein the alkylene group may optionally be further substituted with one or more fluoro groups; R3and RL2, together with the atoms to which they are attached, form a 5- to 7- membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered - 142 - saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 5 or R3, R21and RL2may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 10 fluorocyclopropyl group; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 15 For example, the compound may be a compound of Formula (XVa) as defined above, wherein: X1is N or C-H; X2is N or C-H; Q1is O, S, N-H or N-RQ1; 20 RQ1is selected from a methyl or fluoromethyl group; m is 1 or 2; n is 1 or 2; p is 0, 1 or 2; and q is 1 or 2; 25 provided that: m + n = 2 or 3; and p + q = 2 or 3; r is 0; s is 0; 30 R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group is 35 substituted with one group RL2, and wherein the alkylene group may optionally be further substituted with one or more fluoro groups; R3, R21and RL2, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10- - 143 - membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and 5 each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. Typically in such an example, at least one of X1and X2is N. More typically, X1is N or 10 C-H and X2is N. Most typically, X1is N and X2is N. In a further example, the compound may be a compound of Formula (XVa) as defined above, wherein: X1is N or C-H; 15 X2is N or C-H; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; m is 1 or 2; n is 1 or 2; 20 p is 0, 1 or 2; and q is 1 or 2; provided that: m + n = 2 or 3; and p + q = 2 or 3; 25 r is 0; s is 0; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 30 fluorocyclopropyl group; L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group is substituted with one group RL2, and wherein the alkylene group may optionally be further substituted with one or more fluoro groups; 35 R3and RL2, together with the atoms to which they are attached, form a 5- to 7- membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; - 144 - R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and 5 each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. Typically in such an example, at least one of X1and X2is N. More typically, X1is N or 10 C-H and X2is N. Most typically, X1is N and X2is N. In a further aspect of the seventh exemplary embodiment: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group is substituted with two groups RL2, and wherein the alkylene group may optionally be 15 further substituted with one or more fluoro groups; the two RL2, together with the carbon atom or carbon atoms to which they are attached, form a C3-C6 cycloalkylene group, wherein the C3-C6 cycloalkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 20 R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 25 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon 30 atoms. For example, the compound may be a compound of Formula (XVa) as defined above, wherein: X1is N or C-H; 35 X2is N or C-H; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; m is 1 or 2; - 145 - n is 1 or 2; p is 0, 1 or 2; and q is 1 or 2; provided that: 5 m + n = 2 or 3; and p + q = 2 or 3; r is 0; s is 0; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 10 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group is substituted with two groups RL2, and wherein the alkylene group may optionally be 15 further substituted with one or more fluoro groups; the two RL2, together with the carbon atom or carbon atoms to which they are attached, form a C3-C6 cycloalkylene group, wherein the C3-C6 cycloalkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 20 R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 25 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon 30 atoms. Typically in such an example, at least one of X1and X2is N. More typically, X1is N or C-H and X2is N. Most typically, X1is N and X2is N. 35 In an additional aspect of the seventh exemplary embodiment: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the - 146 - -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; 5 R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 10 RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; 15 provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. For example, the compound may be a compound of Formula (XVa) as defined above, wherein: 20 X1is N or C-H; X2is N or C-H; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; m is 1 or 2; 25 n is 1 or 2; p is 0, 1 or 2; and q is 1 or 2; provided that: m + n = 2 or 3; and 30 p + q = 2 or 3; r is 0; s is 0; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; 35 R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the - 147 - the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or 5 more fluoro groups; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 10 R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and 15 each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. Typically in such an example, at least one of X1and X2is N. More typically, X1is N or 20 C-H and X2is N. Most typically, X1is N and X2is N. In an eighth exemplary embodiment, there is provided a compound of Formula (Xb) as defined above, wherein: X1is N, C-H or C-Hal; 25 X2is N, C-H or C-Hal; and X3is N, C-H or C-Hal; provided that no more than two of X1, X2and X3are N; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; 30 A1is N, C-H or C-Hal; A2is N, C-H or C-Hal; A3is N, C-H or C-Hal; and A4is N, C-H or C-Hal; provided that no more than one of A1, A2, A3and A4is N; 35 each Hal is independently selected from a fluoro, chloro or bromo group; r is 0, 1 or 2; s is 0, 1 or 2; t is 1 or 2; - 148 - each R13is independently selected from a methyl or fluoromethyl group; L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the 5 -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 10 fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 15 R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein 20 the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 25 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted 30 with one or more fluoro groups and / or one or two groups RL3; or R21and R22may together with the nitrogen atom to which they are attached form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 35 or R3, R21and any RL2may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may - 149 - optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon 5 atoms. Typically in accordance with the eighth exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. 10 Typically in accordance with the eighth exemplary embodiment, r is 0, s is 0, and t is 1. In one aspect of the eighth exemplary embodiment: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may 15 optionally be substituted with one or more fluoro groups and / or one or two groups RL2; each RL2is independently selected from a methyl or a fluoromethyl group; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 20 R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; or R21and R22may, together with the nitrogen atom to which they are 25 attached, form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon 30 atoms. For example, the compound may be a compound of Formula (XVb) as defined above, wherein: X1is N or C-H; 35 X2is N or C-H; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; r is 0; - 150 - s is 0; t is 0; L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups 5 RL2; each RL2is independently selected from a methyl or a fluoromethyl group; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 10 fluorocyclopropyl group; and R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; or R21and R22may, together with the nitrogen atom to which they are attached, form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein 15 the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 20 Typically in such an example, at least one of X1and X2is N. More typically, X1is N or C-H and X2is N. Most typically, X1is N and X2is N. In another aspect of the eighth exemplary embodiment: 25 L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the 30 -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 35 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered - 151 - saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon 5 atoms. For example, the compound may be a compound of Formula (XVb) as defined above, wherein: X1is N or C-H; 10 X2is N or C-H; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; r is 0; s is 0; 15 t is 0; L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the 20 alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 25 R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered 30 saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 35 Typically in such an example, at least one of X1and X2is N. More typically, X1is N or C-H and X2is N. Most typically, X1is N and X2is N. - 152 - In a ninth exemplary embodiment, there is provided a compound of Formula (Xd) as defined above, wherein: X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; and 5 X3is N, C-H or C-Hal; provided that no more than two of X1, X2and X3are N; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; A1is N, C-H or C-Hal; 10 A2is N, C-H or C-Hal; A3is N, C-H or C-Hal; and A4is N, C-H or C-Hal; provided that no more than one of A1, A2, A3and A4is N; each Hal is independently selected from a fluoro, chloro or bromo group; 15 m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: 20 m + n = 2 or 3; and p + q = 2 or 3; and wherein: r is 0, 1 or 2; s is 0, 1 or 2; 25 R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; each R13is independently selected from a methyl or fluoromethyl group. 30 L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- 35 group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; - 153 - R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 5 R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein 10 the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 15 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted 20 with one or more fluoro groups and / or one or two groups RL3; or R21and R22may together with the nitrogen atom to which they are attached form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 25 or R3, R21and any RL2may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and 30 each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. Typically in accordance with the ninth exemplary embodiment, at least one of X2and 35 X3is N. Most typically, X2is N. Typically in accordance with the ninth exemplary embodiment: m is 1 or 2; - 154 - n is 1 or 2; p is 0, 1 or 2; and q is 1 or 2; provided that: 5 m + n = 2 or 3; and p + q = 2 or 3; r is 0; and s is 0. 10 In one aspect of the ninth exemplary embodiment: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the 15 alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 20 R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered 25 saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 30 For example, the compound may be a compound of Formula (XVd) as defined above, wherein: X1is N or C-H; X2is N or C-H; 35 Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; m is 1 or 2; n is 1 or 2; - 155 - p is 0, 1 or 2; and q is 1 or 2; provided that: m + n = 2 or 3; and 5 p + q = 2 or 3;; r is 0; s is 0; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; 10 R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the 15 -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 20 fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 25 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon 30 atoms. Typically in such an example, at least one of X1and X2is N. More typically, X1is N or C-H and X2is N. Most typically, X1is N and X2is N. 35 In a tenth exemplary embodiment, there is provided a compound of Formula (Xe) as defined above, wherein: X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; and - 156 - X3is N, C-H or C-Hal; provided that no more than two of X1, X2and X3are N; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; 5 A1is N, C-H or C-Hal; A2is N, C-H or C-Hal; A3is N, C-H or C-Hal; and A4is N, C-H or C-Hal; provided that no more than one of A1, A2, A3and A4is N; 10 each Hal is independently selected from a fluoro, chloro or bromo group; X12is O or NR12; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; and 15 q is 0, 1, 2, 3 or 4; provided that: m + n = 3 or 4; p + q = 3 or 4; when m = 0, q is 1, 2, 3 or 4 and p is 1, 2, 3 or 4; 20 when n = 0, q is 1, 2, 3 or 4 and p is 1, 2, 3 or 4; when p = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and when q = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and wherein: r is 0, 1 or 2; 25 s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 30 each R13is independently selected from a methyl or fluoromethyl group; L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the 35 -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; - 157 - R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 5 R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL2is independently selected from a methyl or fluoromethyl group, or any10 two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 15 or R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, 20 form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R21and R22may together with the nitrogen atom to which they are attached form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 25 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may 30 optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 35 Typically in accordance with the tenth exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. - 158 - Typically in accordance with the tenth exemplary embodiment: m is 1 or 2; n is 1 or 2; p is 0, 1 or 2; and 5 q is 2 or 3; provided that: m + n = 3 or 4; and p + q = 3 or 4; r is 0; and 10 s is 0. In one aspect of the tenth exemplary embodiment: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the 15 the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; 20 R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 25 RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; 30 provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. For example, the compound may be a compound of Formula (XVe) as defined above, wherein: 35 X1is N or C-H; X2is N or C-H; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; - 159 - X12is O or NR12; m is 1 or 2; n is 1 or 2; p is 0, 1 or 2; and 5 q is 2 or 3; provided that: m + n = 3 or 4; and p + q = 3 or 4; r is 0; 10 s is 0; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 15 L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the 20 -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 25 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or 30 more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 35 Typically in such an example, at least one of X1and X2is N. More typically, X1is N or C-H and X2is N. Most typically, X1is N and X2is N. - 160 - In an eleventh exemplary embodiment, there is provided a compound of Formula (Xf) as defined above, wherein: X1is N, C-H or C-Hal; X2is N, C-H or C-Hal; and 5 X3is N, C-H or C-Hal; provided that no more than two of X1, X2and X3are N; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; A1is N, C-H or C-Hal; 10 A2is N, C-H or C-Hal; A3is N, C-H or C-Hal; and A4is N, C-H or C-Hal; provided that no more than one of A1, A2, A3and A4is N; each Hal is independently selected from a fluoro, chloro or bromo group; 15 m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: 20 m + n = 3 or 4; p + q = 2 or 3; when m = 0, p is 1, 2 or 3; when n = 0, p is 1, 2 or 3; and when p = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; 25 and wherein: r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; 30 each R13is independently selected from a methyl or fluoromethyl group; L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the 35 -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; - 161 - R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 5 R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL2is independently selected from a methyl or fluoromethyl group, or any10 two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; 15 or R3and any RL2may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, 20 form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R21and R22may together with the nitrogen atom to which they are attached form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 25 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may 30 optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 35 Typically in accordance with the eleventh exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. - 162 - Typically in accordance with the eleventh exemplary embodiment: m is 1 or 2; n is 1 or 2; p is 1 or 2; and 5 q is 1 or 2; provided that: m + n = 3 or 4; and p + q = 2 or 3; r is 0; and 10 s is 0. In one aspect of the eleventh exemplary embodiment: L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups 15 RL2; each RL2is independently selected from a methyl or a fluoromethyl group; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 20 fluorocyclopropyl group; and R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; or R21and R22may, together with the nitrogen atom to which they are attached, form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein 25 the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. 30 For example, the compound may be a compound of Formula (XVf) as defined above, wherein: X1is N or C-H; X2is N or C-H; 35 Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; m is 1 or 2; n is 1 or 2; - 163 - p is 1 or 2; and q is 1 or 2; provided that: m + n = 3 or 4; and 5 p + q = 2 or 3; r is 0; and s is 0; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; 10 L2is a C2-C4 straight-chained alkylene group, wherein the alkylene group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; each RL2is independently selected from a methyl or a fluoromethyl group; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 15 fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and R22is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 20 or R21and R22may, together with the nitrogen atom to which they are attached, form a 3- to 5-membered saturated monocyclic heterocyclic group, wherein the 3- to 5-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; 25 provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. Typically in such an example, at least one of X1and X2is N. More typically, X1is N or C-H and X2is N. Most typically, X1is N and X2is N. 30 In another aspect of the eleventh exemplary embodiment: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the 35 -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; - 164 - R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 5 R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and 10 each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. For example, the compound may be a compound of Formula (XVf) as defined above, 15 wherein: X1is N or C-H; X2is N or C-H; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; 20 m is 1 or 2; n is 1 or 2; p is 1 or 2; and q is 1 or 2; provided that: 25 m + n = 3 or 4; and p + q = 2 or 3; r is 0; and s is 0; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 30 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group is substituted with one group RL2, and wherein the 35 alkylene, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be further substituted with one or more fluoro groups; - 165 - R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; R22is hydrogen or a -CO-R220, -SO-R220, -SO2-R220, C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; 5 R220is a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and 10 each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 10 carbon atoms. Typically in such an example, at least one of X1and X2is N. More typically, X1is N or 15 C-H and X2is N. Most typically, X1is N and X2is N. In a twelfth exemplary embodiment, there is provided a compound of Formula (XIa) as defined above, wherein: X1is N, C-H or C-Hal; 20 X2is N, C-H or C-Hal; and X3is N, C-H or C-Hal; provided that no more than two of X1, X2and X3are N; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; 25 A1is N, C-H or C-Hal; A2is N, C-H or C-Hal; A3is N, C-H or C-Hal; and A4is N, C-H or C-Hal; provided that no more than one of A1, A2, A3and A4is N; 30 each Hal is independently selected from a fluoro, chloro or bromo group; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; 35 provided that: m + n = 2 or 3; p + q = 2 or 3; when m = 0, q is 1, 2 or 3; - 166 - when n = 0, p is 1, 2 or 3; when p = 0, n is 1, 2 or 3; and when q = 0, m is 1, 2 or 3; and wherein: 5 r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 10 fluorocyclopropyl group; each R13is independently selected from a methyl or fluoromethyl group; L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the 15 -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or one or two groups RL2; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or 20 fluorocyclopropyl group; R21is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the atom or atoms to which they are attached, form a C3- 25 C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3and any RL2may, together with the atoms to which they are attached, 30 form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or any RL2and R21may, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 35 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 8- to 10-membered saturated fused bicyclic heterocyclic group, - 167 - wherein the 8- to 10-membered saturated fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; 5 provided that the group -CO-N(R3)-L2-OR21contains no more than 10 carbon atoms. Typically in accordance with the twelfth exemplary embodiment, at least one of X2and X3is N. Most typically, X2is N. 10 Typically in accordance with the twelfth exemplary embodiment: m is 1 or 2; n is 1 or 2; p is 0, 1 or 2; and 15 q is 1 or 2; provided that: m + n = 2 or 3; and p + q = 2 or 3; r is 0; and 20 s is 0. In one aspect of the twelfth exemplary embodiment: L2is a C2-C5 straight-chained alkylene group, wherein the alkylene group is substituted with one group RL2, and wherein the alkylene group may optionally be 25 further substituted with one or more fluoro groups; R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered 30 saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two groups RL3; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-OR21contains no more than 10 carbon atoms. 35 For example, the compound may be a compound of Formula (XVIa) as defined above, wherein: X1is N or C-H; - 168 - X2is N or C-H; Q1is O, S, N-H or N-RQ1; RQ1is selected from a methyl or fluoromethyl group; m is 1 or 2; 5 n is 1 or 2; p is 0, 1 or 2; and q is 1 or 2; provided that: m + n = 2 or 3; and 10 p + q = 2 or 3; r is 0; s is 0; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; 15 R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; L2is a C2-C5 straight-chained alkylene group, wherein the alkylene group is substituted with one group RL2, and wherein the alkylene group may optionally be further substituted with one or more fluoro groups; 20 R3is hydrogen or a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; RL2and R21, together with the atoms to which they are attached, form a 5- to 7-membered saturated monocyclic heterocyclic group, wherein the 5- to 7-membered saturated monocyclic heterocyclic group may o...

Claims

1. - 362 - Claims 1. A compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof; wherein: R1is a bicyclic or a tricyclic group, wherein the bicyclic or the tricyclic group is non-aromatic, and wherein the bicyclic or the tricyclic group may optionally be substituted with one or more groups each independently selected from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; R2and R3are each independently selected from hydrogen or a C1-C12 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more halo, oxo (=O) and / or -NO2 groups, wherein the saturated hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; or R2and R3together with the nitrogen atom to which they are attached form a 3- to 12-membered saturated cyclic group, wherein the saturated cyclic group may optionally be substituted with one or more substituents each independently selected - 363 - from a halo, oxo (=O), -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more halo, oxo (=O) and / or -NO2 groups, wherein the saturated hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the saturated hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; X1is N, C-H, C-Hal or C-RX1; X2is N, C-H, C-Hal or C-RX2; X3is N, C-H, C-Hal or C-RX3; and X4is N or C; provided that no more than three of X1, X2, X3and X4are N; RX1, RX2and RX3are each independently selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; Q1is O, S, N, N-H, N-RQ1, C-H, C-Hal, or C-RQ2; RQ1is selected from a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of RQ1that is directly attached to the nitrogen atom of N-RQ1is a carbon atom; RQ2is selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 - 364 - groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; A1is N, C-H, C-Hal or C-RA1; A2is N, C-H, C-Hal or C-RA2; A3is N, C-H, C-Hal or C-RA3; A4is N, C-H, C-Hal or C-RA4; and A5is N or C; provided that no more than three of A1, A2, A3, A4and A5are N; RA1, RA2, RA3and RA4are each independently selected from -OH, -SH, -NH2, -SO2H, -SO3H, -SO2NH2, -NO2, or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo and / or -NO2 groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety in the hydrocarbyl group may optionally be substituted with one or two groups each independently selected from oxo (=O) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; A6is N or C; and each Hal is independently selected from a fluoro, chloro, bromo or iodo group.

2. A compound as claimed in claim 1, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein at least one of X2and X3is N.

3. A compound as claimed in claim 2, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein X2is N.

4. A compound as claimed in claim 1, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein X2is C-H, C-Hal or C-RX2.

5. A compound as claimed in claim 3 or claim 4, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein: X1is N, C-H, C-Hal or C-RX1; X3is N, C-H, C-Hal or C-RX3; and X4is C; provided that no more than two of X1, X2and X3are N; and - 365 - wherein RX1, RX2and RX3are each independently selected from a C1-C4 saturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton.

6. A compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R1is a non-aromatic fused bicyclic heterocyclic group, wherein the non-aromatic fused bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

7. A compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R1has the formula: wherein: m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: m + n = 2 or 3; p + q = 2 or 3; when m = 0, q is 1, 2 or 3; when n = 0, p is 1, 2 or 3; when p = 0, n is 1, 2 or 3; and - 366 - when q = 0, m is 1, 2 or 3; and wherein: r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each R13is independently selected from a methyl or fluoromethyl group.

8. A compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R1has the formula: wherein: r is 0, 1 or 2; s is 0, 1 or 2; t is 1 or 2; and each R13is independently selected from a methyl or fluoromethyl group.

9. A compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R1has the formula: wherein: m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: m + n = 2 or 3; and p + q = 2 or 3; - 367 - and wherein: r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each R13is independently selected from a methyl or fluoromethyl group.

10. A compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R1is a non-aromatic spiro bicyclic heterocyclic group, wherein the non-aromatic spiro bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R11, wherein each R11is independently selected from -OH, -NH2, or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

11. A compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R1has the formula: wherein: X12is O or NR12; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; and q is 0, 1, 2, 3 or 4; provided that: m + n = 3 or 4; p + q = 3 or 4; when m = 0, q is 1, 2, 3 or 4 and p is 1, 2, 3 or 4; - 368 - when n = 0, q is 1, 2, 3 or 4 and p is 1, 2, 3 or 4; when p = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and when q = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and wherein: r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-R120group; R120is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group; and each R13is independently selected from a methyl or fluoromethyl group.

12. A compound as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R1has the formula: wherein: m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; and q is 0, 1, 2 or 3; provided that: m + n = 3 or 4; p + q = 2 or 3; when m = 0, p is 1, 2 or 3; when n = 0, p is 1, 2 or 3; and when p = 0, m is 1, 2, 3 or 4 and n is 1, 2, 3 or 4; and wherein: r is 0, 1 or 2; s is 0, 1 or 2; R12is hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; and each R13is independently selected from a methyl or fluoromethyl group. - 369 - 13. A compound as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein: R2is a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one nitrogen atom in its carbon skeleton, wherein said nitrogen atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton; or R2is a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one oxygen atom in its carbon skeleton, wherein said oxygen atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton; or R2is a C1-C10 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include one or two cyclic groups, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro and / or one or two oxo (=O) groups, wherein the saturated hydrocarbyl group includes at least one sulphur atom in its carbon skeleton, wherein said sulphur atom is not directly attached to a sp2hybridised carbon atom, and wherein the saturated hydrocarbyl group may optionally include one or two further heteroatoms each independently selected from N and O in its carbon skeleton; and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; or R2and R3together with the nitrogen atom to which they are attached form a 6- or 7-membered saturated monocyclic group or a 7- to 10-membered saturated bicyclic group, wherein the monocyclic group or the bicyclic group includes at least one further ring nitrogen atom, wherein said further ring nitrogen atom is not directly attached to a sp2hybridised carbon atom, and wherein the monocyclic group or the bicyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R24; or R2and R3together with the nitrogen atom to which they are attached form a 6- or 7-membered saturated monocyclic group or a 7- to 10-membered saturated bicyclic group, wherein the monocyclic group or the bicyclic group includes at least - 370 - one ring oxygen atom, wherein said ring oxygen atom is not directly attached to a sp2hybridised carbon atom, and wherein the monocyclic group or the bicyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R24; or R2and R3together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated monocyclic group or a 7- to 10-membered saturated bicyclic group, wherein the monocyclic group or the bicyclic group is substituted with a -N(R25)2 group, and wherein the monocyclic group or the bicyclic group may optionally be further substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R24; or R2and R3together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated monocyclic group or a 7- to 10-membered saturated bicyclic group, wherein the monocyclic group or the bicyclic group is substituted with a -OR25group, and wherein the monocyclic group or the bicyclic group may optionally be further substituted with one or more fluoro groups and / or one or two oxo (=O) groups, and / or one or two groups R24; each R24is independently selected from -OH, -NH2, or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton; and each R25is independently selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group, or any two R25attached to the same nitrogen atom may together form a C2-C4 allkylene or C2-C4 fluoroallkylene group.

14. A compound as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein -CONR2R3has the formula: wherein: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the - 371 - -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon atom of the alkylene or the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group that is directly attached to the nitrogen atom of -NR21R22is not substituted with an oxo (=O) group; R3is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R3that is directly attached to the nitrogen atom of N-R3is a carbon atom; R21is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R21that is directly attached to the nitrogen atom of -NR21R22is a carbon atom that is not substituted with an oxo (=O) group; and R22is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R22that is directly attached to the nitrogen atom of -NR21R22is a carbon atom that is not substituted with an oxo (=O) group; or R22is selected from a -CO-R220, -SO-R220or -SO2-R220group; R220is a C1-C5 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated - 372 - hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the carbon atom or carbon atoms to which they are attached, form a C3-C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic group, wherein the 6- or 7- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 6- or 7-membered saturated monocyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or any RL2and R21may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 4- to 7-membered saturated monocyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or R21and R22may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 3- to 6- membered saturated monocyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein - 373 - the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or R3, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10- membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the three ring atoms of the 7- to 10-membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are all carbon atoms that are not substituted with an oxo (=O) group; or any two RL2and R21may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are both carbon atoms that are not substituted with an oxo (=O) group; or any RL2, R21and R22may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the three ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the nitrogen atom of -NR21R22are all carbon atoms that are not substituted with an oxo (=O) group; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-NR21R22contains no more than 12 carbon atoms. - 374 - 15. A compound as claimed in claim 14, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R21is not hydrogen and R22is not hydrogen.

16. A compound as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein -CONR2R3has the formula: wherein: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon atom of the alkylene or the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group that is directly attached to the oxygen atom of -OR21is not substituted with an oxo (=O) group; R3is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R3that is directly attached to the nitrogen atom of N-R3is a carbon atom; R21is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of - 375 - any saturated hydrocarbyl group of R21that is directly attached to the oxygen atom of -OR21is a carbon atom that is not substituted with an oxo (=O) group; and each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the carbon atom or carbon atoms to which they are attached, form a C3-C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic group, wherein the 6- or 7- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 6- or 7-membered saturated monocyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group; or any RL2and R21may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 4- to 7-membered saturated monocyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group; or R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the - 376 - oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group; or any two RL2and R21may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the oxygen atom of -OR21are both carbon atoms that are not substituted with an oxo (=O) group; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-OR21contains no more than 12 carbon atoms.

17. A compound as claimed in claim 16, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R21is not hydrogen.

18. A compound as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein -CONR2R3has the formula: wherein: L2is a C2-C6 straight-chained alkylene group or a -CH2CH2-O-CH2CH2-, -CH2CH2CH2-O-CH2CH2-, -CH2CH2-O-CH2CH2CH2-, -CH2CH2-NH-CH2CH2-, -CH2CH2CH2-NH-CH2CH2- or -CH2CH2-NH-CH2CH2CH2- group, wherein the alkylene, the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL2, provided that the carbon atom of the alkylene or the -CH2CH2-O-CH2CH2-, the -CH2CH2CH2-O-CH2CH2-, the -CH2CH2-O-CH2CH2CH2-, the -CH2CH2-NH-CH2CH2-, the -CH2CH2CH2-NH-CH2CH2- or the -CH2CH2-NH-CH2CH2CH2- group that is directly attached to the sulphur atom of -SR21is not substituted with an oxo (=O) group; R3is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single - 377 - cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R3that is directly attached to the nitrogen atom of N-R3is a carbon atom; R21is hydrogen or a C1-C6 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any saturated hydrocarbyl group of R21that is directly attached to the sulphur atom of -SR21is a carbon atom that is not substituted with an oxo (=O) group; and each RL2is independently selected from a methyl or fluoromethyl group, or any two RL2may, together with the atom or atoms to which they are attached, form a C3- C6 cycloalkylene group or a 4- to 7-membered saturated heterocyclic group, wherein the C3-C6 cycloalkylene group or the 4- to 7-membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and any RL2may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3and R21may, together with the atoms to which they are attached, form a 6- or 7-membered saturated monocyclic heterocyclic group, wherein the 6- or 7- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 6- or 7-membered saturated monocyclic heterocyclic group that are directly attached to the sulphur atom of -SR21are both carbon atoms that are not substituted with an oxo (=O) group; or any RL2and R21may, together with the atoms to which they are attached, form a 4- to 7-membered saturated monocyclic heterocyclic group, wherein the 4- to 7-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 4- to 7-membered - 378 - saturated monocyclic heterocyclic group that are directly attached to the sulphur atom of -SR21are both carbon atoms that are not substituted with an oxo (=O) group; or R3and any two RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3; or R3, R21and any RL2may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the sulphur atom of -SR21are both carbon atoms that are not substituted with an oxo (=O) group; or any two RL2and R21may, together with the atoms to which they are attached, form a 7- to 10-membered saturated bicyclic heterocyclic group, wherein the 7- to 10-membered saturated bicyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group and / or one, two, three or four groups RL3, provided that the two ring atoms of the 7- to 10- membered saturated bicyclic heterocyclic group that are directly attached to the sulphur atom of -SR21are both carbon atoms that are not substituted with an oxo (=O) group; and each RL3is independently selected from a methyl or a fluoromethyl group; provided that the group -CO-N(R3)-L2-SR21contains no more than 12 carbon atoms.

19. A compound as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein: R2is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; and R3is selected from hydrogen or a C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C4 cycloalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl or fluorocyclopropylmethyl group; or R2and R3together with the nitrogen atom to which they are attached form a azetidinyl, pyrrolidinyl, piperidinyl or azepanyl group, any of which may optionally be fluoro-substituted. - 379 - 20. A compound as claimed in any one of claims 1 to 19, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein the group -CONR2R3is acyclic.

21. A compound as claimed in any one of claims 1 to 20, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein Q1is O, S, N-H or N-RQ1, wherein RQ1is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl, cyclopropylmethyl, fluorocyclopropylmethyl or -CO-RQ3group, and wherein RQ3is selected from a C1-C3 alkyl, C1-C3 fluoroalkyl, cyclopropyl or fluorocyclopropyl group.

22. A compound as claimed in any one of claims 1 to 21, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein: A1is N, C-H, C-Hal or C-RA1; A2is N, C-H, C-Hal or C-RA2; A3is N, C-H, C-Hal or C-RA3; A4is N, C-H, C-Hal or C-RA4; A5is C; and RA1, RA2, RA3and RA4are each independently selected from a C1-C4 saturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or a single oxo (=O) group, and wherein the hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton; provided that no more than one of A1, A2, A3and A4is N; and provided that no more than two of A1, A2, A3and A4are C-RA1, C-RA2, C-RA3or C-RA4.

23. A compound as claimed in any one of claims 1 to 22, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein A6is N.

24. A compound as claimed in any one of claims 1 to 23, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein each Hal is independently selected from a fluoro, chloro or bromo group. - 380 - 25. A compound as claimed in any one of claims 1 to 24, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein the compound is a compound of Formula (VII): Formula (VII) wherein Q1is O, S, N-H or N-RQ1, and R1, R2, R3, X1-X3, A1-A4and RQ1are as defined in accordance with any preceding claim.

26. A compound as claimed in claim 25, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein the compound is a compound of Formula (XII): Formula (XII) wherein Q1is O, S, N-H or N-RQ1, and R1, R2, R3, X1, X2and RQ1are as defined in accordance with any preceding claim.

27. A compound as claimed in claim 25 or claim 26, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein Q1is S or N-H.

28. A compound selected from the group consisting of: - 397 - or a pharmaceutically acceptable salt and / or solvate and / or prodrug of the selected compound.

29. An antibody-drug conjugate comprising a compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in any one of claims 1 to 28.

30. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in any one of claims 1 to 28, or an antibody-drug conjugate as claimed in claim 29, and a pharmaceutically acceptable excipient.

31. A compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in any one of claims 1 to 28, or an antibody-drug conjugate as claimed in claim 29, or a pharmaceutical composition as claimed in claim 30, for use in medicine.

32. A compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in any one of claims 1 to 28, or an antibody-drug - 398 - conjugate as claimed in claim 29, or a pharmaceutical composition as claimed in claim 30, for use in treating cancer.

Images